<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Microorganisms</journal-id><journal-id journal-id-type="iso-abbrev">Microorganisms</journal-id><journal-id journal-id-type="publisher-id">microorganisms</journal-id><journal-title-group><journal-title>Microorganisms</journal-title></journal-title-group><issn pub-type="epub">2076-2607</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9147981</article-id><article-id pub-id-type="doi">10.3390/microorganisms10051052</article-id><article-id pub-id-type="publisher-id">microorganisms-10-01052</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Biological Control of <italic toggle="yes">Acinetobacter baumannii</italic>: In Vitro and In Vivo Activity, Limitations, and Combination Therapies</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7634-0605</contrib-id><name><surname>Havenga</surname><given-names>Benjamin</given-names></name><xref rid="af1-microorganisms-10-01052" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7871-667X</contrib-id><name><surname>Reyneke</surname><given-names>Brandon</given-names></name><xref rid="af1-microorganisms-10-01052" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2567-5402</contrib-id><name><surname>Waso-Reyneke</surname><given-names>Monique</given-names></name><xref rid="af2-microorganisms-10-01052" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ndlovu</surname><given-names>Thando</given-names></name><xref rid="af3-microorganisms-10-01052" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Sehaam</given-names></name><xref rid="af2-microorganisms-10-01052" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1559-9485</contrib-id><name><surname>Khan</surname><given-names>Wesaal</given-names></name><xref rid="af1-microorganisms-10-01052" ref-type="aff">1</xref><xref rid="c1-microorganisms-10-01052" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Sang</surname><given-names>Mee Kyung</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-microorganisms-10-01052"><label>1</label>Department of Microbiology, Faculty of Science, Stellenbosch University, Private Bag X1, Stellenbosch 7602, South Africa; <email>18339697@sun.ac.za</email> (B.H.); <email>breyneke@sun.ac.za</email> (B.R.)</aff><aff id="af2-microorganisms-10-01052"><label>2</label>Faculty of Health Sciences, University of Johannesburg, Doornfontein 2028, South Africa; <email>221029180@student.uj.ac.za</email> (M.W.-R.); <email>skhan@uj.ac.za</email> (S.K.)</aff><aff id="af3-microorganisms-10-01052"><label>3</label>Department of Biological Sciences, Faculty of Science, University of Botswana, Private Bag UB, Gaborone 0022, Botswana; <email>ndlovut@ub.ac.bw</email></aff><author-notes><corresp id="c1-microorganisms-10-01052"><label>*</label>Correspondence: <email>wesaal@sun.ac.za</email>; Tel.: +27-21-808-5804</corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>5</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2022</year></pub-date><volume>10</volume><issue>5</issue><elocation-id>1052</elocation-id><history><date date-type="received"><day>20</day><month>4</month><year>2022</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The survival, proliferation, and epidemic spread of <italic toggle="yes">Acinetobacter baumannii</italic> (<italic toggle="yes">A. baumannii</italic>) in hospital settings is associated with several characteristics, including resistance to many commercially available antibiotics as well as the expression of multiple virulence mechanisms. This severely limits therapeutic options, with increased mortality and morbidity rates recorded worldwide. The World Health Organisation, thus, recognises <italic toggle="yes">A. baumannii</italic> as one of the critical pathogens that need to be prioritised for the development of new antibiotics or treatment. The current review will thus provide a brief overview of the antibiotic resistance and virulence mechanisms associated with <italic toggle="yes">A. baumannii</italic>&#x02019;<italic toggle="yes">s</italic> &#x0201c;persist and resist strategy&#x0201d;. Thereafter, the potential of biological control agents including secondary metabolites such as biosurfactants [lipopeptides (surfactin and serrawettin) and glycolipids (rhamnolipid)] as well as predatory bacteria (<italic toggle="yes">Bdellovibrio bacteriovorus</italic>) and bacteriophages to directly target <italic toggle="yes">A. baumannii</italic>, will be discussed in terms of their in vitro and in vivo activity. In addition, limitations and corresponding mitigations strategies will be outlined, including curtailing resistance development using combination therapies, product stabilisation, and large-scale (up-scaling) production.</p></abstract><kwd-group><kwd><italic toggle="yes">Acinetobacter baumannii</italic></kwd><kwd>biological control</kwd><kwd>biosurfactants</kwd><kwd><italic toggle="yes">Bdellovibrio bacteriovorus</italic></kwd><kwd>bacteriophages</kwd></kwd-group><funding-group><award-group><funding-source>National Research Foundation of South Africa</funding-source><award-id>NRF UID 130356</award-id></award-group><funding-statement>The authors thank the financial support provided by the National Research Foundation of South Africa (Grant Number: NRF UID 130356 (09.12.2021) for funding. Opinions expressed and conclusions arrived at are those of the authors and are not necessarily to be attributed to the National Research Foundation.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-microorganisms-10-01052"><title>1. Introduction</title><p><italic toggle="yes">Acinetobacter baumannii</italic> (<italic toggle="yes">A. baumannii</italic>) is one of the primary microorganisms linked to hospital-acquired infections such as central line-associated bacteraemia, ventilator-associated pneumonia (VAP), as well as meningitis, bioprosthetic tricuspid valve endocarditis, and urinary tract infections (UTIs) [<xref rid="B1-microorganisms-10-01052" ref-type="bibr">1</xref>]. The global estimated incidence rate of <italic toggle="yes">A. baumannii</italic> infections is approximately 1 million cases annually, with crude mortality rates ranging from 20 to 80% [<xref rid="B2-microorganisms-10-01052" ref-type="bibr">2</xref>,<xref rid="B3-microorganisms-10-01052" ref-type="bibr">3</xref>]. Previous studies have indicated that several risk factors predispose patients to <italic toggle="yes">A. baumannii</italic> infection including age (premature babies), immunosuppression, prior hospitalisation [exposure to intensive care unit (ICU)], hospitalisation duration, surgery (invasive procedures), presence of medical indwelling devices (intravascular catheters, urinary catheter, or drainage tubes), and prior or inappropriate antimicrobial therapy [<xref rid="B4-microorganisms-10-01052" ref-type="bibr">4</xref>].</p><p>Moreover, the extensive resistome of <italic toggle="yes">A. baumannii</italic> hampers the efficacy of mono-therapeutic options, and while antibiotic combination therapies have been shown to exhibit in vitro and in vivo activity against various antibiotic-resistant strains, clinical trials have not provided sufficient data to confirm that combination therapies are superior for the treatment of <italic toggle="yes">A. baumannii</italic> infections [<xref rid="B5-microorganisms-10-01052" ref-type="bibr">5</xref>]. In addition, <italic toggle="yes">A. baumannii</italic>&#x02019;s virulome, including cellular envelope factors, outer membrane proteins, secretion systems, phospholipases, as well as biofilm formation, allows it to persist under unfavourable environmental conditions for extended time periods, enhancing the colonisation and subsequent infection of susceptible hosts [<xref rid="B6-microorganisms-10-01052" ref-type="bibr">6</xref>].</p><p>There is thus an urgent need for the research and development of alternative or novel approaches that could be used for the treatment of <italic toggle="yes">A. baumannii</italic>-associated infections, with biological control therapeutic options, defined as the elimination or eradication of a population of microorganisms through the introduction of an antagonistic (predatory) microorganism or its associated secondary metabolites, garnering increased interest [<xref rid="B7-microorganisms-10-01052" ref-type="bibr">7</xref>]. For example, microbially derived secondary metabolites such as biosurfactants have been described as alternative or novel antimicrobials due to their functional properties. Lipopeptides and glycolipids are of extreme interest to the pharmaceutical and medical industry as various classes exhibit broad-spectrum in vitro and in vivo antimicrobial, antibiofilm, antiadhesive activity, and low cytotoxicity [<xref rid="B8-microorganisms-10-01052" ref-type="bibr">8</xref>,<xref rid="B9-microorganisms-10-01052" ref-type="bibr">9</xref>,<xref rid="B10-microorganisms-10-01052" ref-type="bibr">10</xref>]. While the biosurfactants exhibit promising functional properties as biological control agents against <italic toggle="yes">A. baumannii</italic>, the application thereof remains limited due to the potential development of resistance and the high cost associated with commercialisation or large-scale (up-scaling) production [<xref rid="B11-microorganisms-10-01052" ref-type="bibr">11</xref>,<xref rid="B12-microorganisms-10-01052" ref-type="bibr">12</xref>,<xref rid="B13-microorganisms-10-01052" ref-type="bibr">13</xref>]. In addition, biological control agents including predatory bacteria [<italic toggle="yes">Bdellovibrio bacteriovorus</italic> (<italic toggle="yes">B. bacteriovorus</italic>)] and bacteriophages have been investigated as alternative or novel antimicrobials as these approaches are considered self-sustaining, highly specific, and result in low resistance frequencies, highlighting their potential use against <italic toggle="yes">A. baumannii</italic> [<xref rid="B14-microorganisms-10-01052" ref-type="bibr">14</xref>,<xref rid="B15-microorganisms-10-01052" ref-type="bibr">15</xref>]. However, while the biological control agents have been observed to exhibit in vitro and in vivo antimicrobial, and antibiofilm activity with limited cytotoxicity (or deleterious effects) following treatment, the potential of developing resistance and environmental stability, are major limitations impeding their potential application against <italic toggle="yes">A. baumannii.</italic></p><p>The current review will thus provide a brief overview of <italic toggle="yes">A. baumannii</italic>&#x02019;<italic toggle="yes">s</italic> environmental persistence (bacterial survival under unfavourable environmental conditions), and antibiotic resistance strategies, primarily facilitated through virulence factors and antibiotic resistance mechanisms [<xref rid="B16-microorganisms-10-01052" ref-type="bibr">16</xref>]. In addition, the therapeutic potential of microbial secondary metabolites [biosurfactants (lipopeptides and glycolipids)] as well as biological control agents including predatory bacteria (<italic toggle="yes">B. bacteriovorus</italic>) and bacteriophages will be discussed in terms of their in vitro and in vivo activity, limitations such as the potential development of resistance, product stabilisation and large-scale (up-scaling) production. Correspondingly, potential mitigation strategies will focus on the methods to curtail resistance development during treatment (combination therapy with commercial antibiotics), product (<italic toggle="yes">B. bacteriovorus</italic> and bacteriophage-derived enzymes) stabilisation for application in the medical/pharmaceutical industries, and large-scale production and optimisation of the biological control agents or their derived products.</p></sec><sec id="sec2-microorganisms-10-01052"><title>2. <italic toggle="yes">Acinetobacter baumannii</italic> Resistome&#x02014;Antibiotic Resistance Mechanisms</title><p><italic toggle="yes">Acinetobacter baumannii</italic> exhibits intrinsic resistance to numerous first-line antibiotics (ampicillin, amoxicillin, amoxicillin-sulbactam, aztreonam, ertapenem, trimethoprim, chloramphenicol, and fosfomycin) and can accumulate and upregulate antibiotic resistance genes through horizontal gene transfer and insertion sequences (ISs) [<xref rid="B17-microorganisms-10-01052" ref-type="bibr">17</xref>]. Multidrug-resistant (MDR) <italic toggle="yes">A. baumannii</italic> strains are classified as non-susceptible to at least one agent in three or more antimicrobial classes (antipseudomonal carbapenems, antipseudomonal penicillins + beta-(&#x003b2;)-lactamase inhibitors, penicillins + &#x003b2;-lactamase inhibitors, aminoglycosides, antipseudomonal fluoroquinolones, extended-spectrum cephalosporins, folate pathway inhibitors, tetracyclines, and polymyxins); extensively drug-resistant (XDR) strains are classified as non-susceptible to at least one agent in all but two or fewer antimicrobial categories (inhibitors of cell wall synthesis, protein synthesis, and DNA or RNA synthesis), while pandrug-resistant (PDR) <italic toggle="yes">A. baumannii</italic> strains are classified as non-susceptible to any agent in all antimicrobial categories [<xref rid="B18-microorganisms-10-01052" ref-type="bibr">18</xref>].</p><p>These antibiotic-resistant <italic toggle="yes">A. baumannii</italic> strains employ an extensive range of enzymatic and non-enzymatic resistance mechanisms (<xref rid="microorganisms-10-01052-t001" ref-type="table">Table 1</xref>). For example, &#x003b2;-lactam resistance amongst <italic toggle="yes">A. baumannii</italic> is primarily mediated by &#x003b2;-lactamases, of which all four Ambler classes (A, B, C, and D) have been detected in various strains [<xref rid="B19-microorganisms-10-01052" ref-type="bibr">19</xref>] (<xref rid="microorganisms-10-01052-t001" ref-type="table">Table 1</xref>). Inherent to all <italic toggle="yes">A. baumannii</italic> isolates is the Ambler class D oxacillinase-51-like (OXA-51) enzyme, which has been observed to facilitate penicillin (benzylpenicillin, ampicillin, ticarcillin, and piperacillin) and carbapenem (imipenem and meropenem) resistance [<xref rid="B1-microorganisms-10-01052" ref-type="bibr">1</xref>]. Carbapenem resistance (imipenem, meropenem, and doripenem) has also been increasing, with a resistance rate ranging from 54.7 to 64.0% recorded amongst <italic toggle="yes">A. baumannii</italic> strains [<xref rid="B20-microorganisms-10-01052" ref-type="bibr">20</xref>]. Moreover, 400 different oxacillinase enzymes, which are clustered into six subgroups (OXA-23, OXA-24, OXA-40, OXA-58, OXA-143, and OXA-235), have been identified in <italic toggle="yes">A. baumannii</italic> [<xref rid="B19-microorganisms-10-01052" ref-type="bibr">19</xref>] (<xref rid="microorganisms-10-01052-t001" ref-type="table">Table 1</xref>). Non-enzymatic &#x003b2;-lactam resistance mechanisms have also been detected in <italic toggle="yes">A. baumannii</italic>, including the outer membrane proteins [OMPs: carbapenem susceptible porin (CarO), OmpA and Omp 33 to 36 kDa (Omp33&#x02013;36)] and resistance-nodulation-division (RND) superfamily type efflux system [<italic toggle="yes">Acinetobacter</italic> drug efflux ATP-binding cassette (AdeABC)] [<xref rid="B21-microorganisms-10-01052" ref-type="bibr">21</xref>] (<xref rid="microorganisms-10-01052-t001" ref-type="table">Table 1</xref>).</p><p>In addition to &#x003b2;-lactamases, <italic toggle="yes">A. baumannii</italic> mediates aminoglycoside resistance through the production of aminoglycoside modifying enzymes (AMEs) including acetyltransferases (<italic toggle="yes">aac(3&#x02032;)-Ia</italic> and <italic toggle="yes">aac(3&#x02032;)-IIa</italic>), nucleotidyltransferases (<italic toggle="yes">ant(2&#x02032;)-Ia</italic>), and phosphotransferases (<italic toggle="yes">aph(3&#x02032;)-Via</italic>) resulting in resistance to tobramycin, kanamycin, amikacin, and gentamicin [<xref rid="B22-microorganisms-10-01052" ref-type="bibr">22</xref>]. Accordingly, <italic toggle="yes">A. baumannii</italic> exhibits resistance rates ranging from 80.0 to 90.0% against tobramycin, amikacin, and gentamicin [<xref rid="B23-microorganisms-10-01052" ref-type="bibr">23</xref>]. Broad-spectrum aminoglycoside (amikacin, gentamicin, kanamycin, and tobramycin) resistance has then been attributed to ribosomal modifications (16S rRNA methylases: <italic toggle="yes">rmtA</italic> to <italic toggle="yes">rmtD</italic>) and non-enzymatic mechanisms such as the overexpression of RND (AdeABC) or multiple antibiotic and toxin extrusion (MATE: AbeM) superfamily efflux pumps [<xref rid="B24-microorganisms-10-01052" ref-type="bibr">24</xref>,<xref rid="B25-microorganisms-10-01052" ref-type="bibr">25</xref>] (<xref rid="microorganisms-10-01052-t001" ref-type="table">Table 1</xref>). Similarly, efflux systems including the MATE superfamily efflux pump (AbeM), RND superfamily type efflux systems (AdeABC, AdeFGH, and AdeIJK), and Small Multidrug Resistance (SMR) protein family (AbeS) have been associated with quinolone resistance amongst <italic toggle="yes">A. baumannii</italic> strains [<xref rid="B26-microorganisms-10-01052" ref-type="bibr">26</xref>]. Tetracycline (doxycycline and minocycline) and glycylcycline (tigecycline) resistance (ranging from 0 to 61.7%) has also been associated with two efflux pump systems including, the RND superfamily type efflux systems (AdeABC and AdeIJK), Major Facilitator Superfamily (MFS: TetA and TetB), and ribosomal protection proteins [Tet(M), Tet(W), Tet(O), and Tet(S)] [<xref rid="B27-microorganisms-10-01052" ref-type="bibr">27</xref>,<xref rid="B28-microorganisms-10-01052" ref-type="bibr">28</xref>] (<xref rid="microorganisms-10-01052-t001" ref-type="table">Table 1</xref>).</p><p>Apart from the efflux systems, quinolone (ciprofloxacin and levofloxacin) resistance, ranging from 75.0 to 97.7%, has been found to be associated with mutations of the DNA gyrase (<italic toggle="yes">gyrA</italic> and <italic toggle="yes">gyrB</italic>) and topoisomerase IV (<italic toggle="yes">parC</italic>), and plasmid-mediated quinolone resistance genes (<italic toggle="yes">qnrA, qnrB,</italic> and <italic toggle="yes">qnrS</italic>) [<xref rid="B29-microorganisms-10-01052" ref-type="bibr">29</xref>,<xref rid="B30-microorganisms-10-01052" ref-type="bibr">30</xref>] (<xref rid="microorganisms-10-01052-t001" ref-type="table">Table 1</xref>). Resistance to tetracycline and glycylcycline (tigecycline) may also be plasmid mediated, with recent studies detecting <italic toggle="yes">tet</italic>(X3), <italic toggle="yes">tet</italic>(X4), <italic toggle="yes">tet</italic>(X5), and <italic toggle="yes">tet</italic>(X6) genes amongst non-<italic toggle="yes">Enterobacteriaceae</italic> including <italic toggle="yes">A. baumannii</italic> [<xref rid="B31-microorganisms-10-01052" ref-type="bibr">31</xref>,<xref rid="B32-microorganisms-10-01052" ref-type="bibr">32</xref>].</p><p>Subsequently, the global emergence of MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic> isolates has led to a resurgence in the use of the last-resort antibiotic, colistin (polymyxin E). However, numerous studies have reported on varying degrees of colistin resistance and heteroresistance amongst <italic toggle="yes">A. baumannii</italic> [<xref rid="B33-microorganisms-10-01052" ref-type="bibr">33</xref>].</p><p>Chromosomally encoded colistin resistance mechanisms amongst <italic toggle="yes">A. baumannii</italic> strains have primarily been associated with: (1) lipopolysaccharide (LPS) modification (<italic toggle="yes">pmrA</italic> and <italic toggle="yes">pmrB</italic> gene mutations; IS<italic toggle="yes">Aba1</italic> insertion upstream of the PmrC homolog EptA (<italic toggle="yes">eptA</italic>) and NaxD); (2) LPS loss (<italic toggle="yes">lpxA</italic>, <italic toggle="yes">lpxC</italic>, and <italic toggle="yes">lpxD</italic> gene mutations; or IS<italic toggle="yes">Aba11</italic> in <italic toggle="yes">lpxA</italic> or <italic toggle="yes">lpxC</italic> genes); the (3) downregulation of export and/or stabilisation proteins of the outer membrane precursors (LpsB, LptD, VacJ, and PldA); and the (4) reduction in cofactor gene expression (biotin) (extensively reviewed by Lima et al. [<xref rid="B34-microorganisms-10-01052" ref-type="bibr">34</xref>]) (<xref rid="microorganisms-10-01052-t001" ref-type="table">Table 1</xref>). More recently, a novel plasmid mediated mobile colistin resistance (<italic toggle="yes">mcr</italic>) gene, previously conserved amongst <italic toggle="yes">Enterobacteriaceae</italic>, was detected in <italic toggle="yes">A. baumannii</italic> strains [<xref rid="B35-microorganisms-10-01052" ref-type="bibr">35</xref>]. The <italic toggle="yes">mcr</italic> gene encodes for a phosphoethanolamine (PEA) transferase that transfers the PEA to lipid A, resulting in a more cationic LPS and thus the repulsion of colistin [<xref rid="B34-microorganisms-10-01052" ref-type="bibr">34</xref>]. To date, two variants, namely, <italic toggle="yes">mcr-1</italic> and <italic toggle="yes">mcr-4.3</italic>, have been detected in various strains of <italic toggle="yes">A. baumannii</italic>; however, no direct correlation was made by Hameed et al. [<xref rid="B36-microorganisms-10-01052" ref-type="bibr">36</xref>] and Ma et al. [<xref rid="B37-microorganisms-10-01052" ref-type="bibr">37</xref>] between the presence of the genes and colistin resistance. Martins-Sorenson et al. [<xref rid="B38-microorganisms-10-01052" ref-type="bibr">38</xref>], however, reported on a direct correlation between the presence of the <italic toggle="yes">mcr-4.3</italic> gene and colistin resistance (65 mg/L) in the clinical <italic toggle="yes">A. baumannii</italic> 597A isolate.</p></sec><sec id="sec3-microorganisms-10-01052"><title>3. <italic toggle="yes">Acinetobacter baumannii</italic> Virulome&#x02014;Virulence Factors and Mechanisms</title><p>In addition to the resistome of MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic> isolates, this opportunistic pathogen employs a variety of virulence factors and mechanisms facilitating survival, which enhances the colonisation and subsequent infection of susceptible hosts. These virulence factors include but are not limited to; cellular envelope factors, outer membrane proteins, secretion systems, phospholipases, and biofilm formation, which concomitantly contribute to the pathogenicity of <italic toggle="yes">A. baumannii</italic> (extensively reviewed by Harding et al. [<xref rid="B16-microorganisms-10-01052" ref-type="bibr">16</xref>]) (<xref rid="microorganisms-10-01052-f001" ref-type="fig">Figure 1</xref>). The cellular envelope factors, including glycoconjugates or glycans (carbohydrates) such as capsular polysaccharides (CPS), LPS, glycosylated proteins, and peptidoglycan, provide an interface between <italic toggle="yes">A. baumannii</italic> and its environment, thus facilitating survival and persistence [<xref rid="B16-microorganisms-10-01052" ref-type="bibr">16</xref>] (<xref rid="microorganisms-10-01052-f001" ref-type="fig">Figure 1</xref>). For example, the CPS of <italic toggle="yes">A. baumannii</italic> has been associated with water retention, which facilitates desiccation tolerance. Tipton et al. [<xref rid="B39-microorganisms-10-01052" ref-type="bibr">39</xref>] observed that acapsular (CPS absent) <italic toggle="yes">A. baumannii</italic> AB5075, exhibited a 2.5-fold decrease in desiccation tolerance in comparison to capsular parental strains. In addition, the acapsular (&#x00394;<italic toggle="yes">wzc</italic>) mutant strain exhibited an 8-log reduction in the colony forming units (CFU) at 24 h post-infection of a murine (mouse lung/lungs) model, in comparison to the wild-type, capsular (<italic toggle="yes">wzc</italic>) strain, indicating that the capsule functions as an important virulence factor in infection and pathogenesis. The LPS has also been linked to desiccation tolerance with Boll et al. [<xref rid="B40-microorganisms-10-01052" ref-type="bibr">40</xref>] demonstrating the association between lipid A acetylation and desiccation tolerance in <italic toggle="yes">A. baumannii</italic>. Moreover, strains of <italic toggle="yes">A. baumannii</italic>, with LPS devoid of the hepta-acylated lipid A, exhibited decreased desiccation tolerance, which was proposed to be due to an increased membrane fluidity resulting in the leakage of water and nutrients [<xref rid="B40-microorganisms-10-01052" ref-type="bibr">40</xref>]. In addition to OMPs, several secretion systems have been detected and associated with virulence amongst <italic toggle="yes">A. baumannii</italic> strains, including the Type II secretion system (T2SS), Type V secretion system (T5SS), and Type VI secretion system (T6SS) [<xref rid="B16-microorganisms-10-01052" ref-type="bibr">16</xref>] (<xref rid="microorganisms-10-01052-f001" ref-type="fig">Figure 1</xref>). The T2SS facilitates the excretion of toxins, hydrolytic enzymes (lipases, lipoproteins, and proteases), aids in the acquisition of nutrients, and is required for in vivo survival and virulence [<xref rid="B41-microorganisms-10-01052" ref-type="bibr">41</xref>,<xref rid="B42-microorganisms-10-01052" ref-type="bibr">42</xref>]. Johnson et al. [<xref rid="B42-microorganisms-10-01052" ref-type="bibr">42</xref>] then demonstrated the association between the T2SS, secretion of lipase (LipA), and pathogenicity in <italic toggle="yes">A. baumannii</italic> using &#x02206;<italic toggle="yes">gspD</italic> (GspD: outer membrane pore) and &#x02206;<italic toggle="yes">gspE</italic> (GspE: ATPase) mutants. Through the generation of <italic toggle="yes">A. baumannii</italic> &#x02206;<italic toggle="yes">gspD</italic> and &#x02206;<italic toggle="yes">gspE</italic> mutants, decreased LipA secretion was achieved resulting in decreased growth and significantly reduced in vivo fitness (decreased colonisation of spleen and liver) in murine (CBA/J mice) models. Therefore, T2SS was proposed to facilitate nutrient acquisition through the excretion of lipase, which allowed for in vivo colonisation, thus contributing to the pathogenesis of <italic toggle="yes">A. baumannii</italic>.</p><p>Other membrane-associated structures, including the OMPs (OmpW, CarO, OprF, OprD, AbuO, TolB, DcaP, Oma87/BamA, NmRmpM, CadF, and LptD), have also been identified as virulence factors in <italic toggle="yes">A. baumannii</italic> [<xref rid="B48-microorganisms-10-01052" ref-type="bibr">48</xref>] (<xref rid="microorganisms-10-01052-f001" ref-type="fig">Figure 1</xref>). The most abundant and extensively studied <italic toggle="yes">A. baumannii</italic> OMP is OmpA (previously referred to as Omp38), which facilitates cell adherence and invasion (observed to be dependent on the host cell type), with respiratory tract epithelial cells (bronchial (NCI-H292) and laryngeal (HEp-2) cells) being more susceptible to infection in comparison to non-respiratory tract epithelial cells (cervical carcinoma (HeLa) cells) [<xref rid="B49-microorganisms-10-01052" ref-type="bibr">49</xref>].</p><p>Through the implementation of numerous surface and extracellular-associated structures, <italic toggle="yes">A. baumannii</italic> is also able to form biofilms, which has been characterised as a major virulence factor contributing to the bacterium&#x02019;s pathogenicity [<xref rid="B6-microorganisms-10-01052" ref-type="bibr">6</xref>,<xref rid="B50-microorganisms-10-01052" ref-type="bibr">50</xref>]. Biofilm formation has also been associated with increased pathogenicity, with Khalil et al. [<xref rid="B51-microorganisms-10-01052" ref-type="bibr">51</xref>] reporting on an increased killing rate (50 to 90%), observed in a larva (<italic toggle="yes">G. mellonella</italic>) model, by strong biofilm-forming <italic toggle="yes">A. baumannii</italic> strains in comparison to moderate and weak biofilm-forming strains. Structures such as the chaperone-usher (Csu) pili and CsuA/BABCDE-independent short pili system, as well as biofilm associated-proteins (Bap or BAP), allow <italic toggle="yes">A. baumannii</italic> to adhere to both abiotic (polyethylene, polystyrene, titanium, and Teflon) and biotic (human bronchial epithelial (H<sub>292</sub>) cells and neonatal keratinocyte cells) surfaces [<xref rid="B52-microorganisms-10-01052" ref-type="bibr">52</xref>] (<xref rid="microorganisms-10-01052-f001" ref-type="fig">Figure 1</xref>). Two Bap-like proteins (BLP: BLP1 and BLP2) have also been identified in different <italic toggle="yes">A. baumannii</italic> strains, facilitating both adherence and biofilm formation on bronchial epithelial (A549) cells [<xref rid="B53-microorganisms-10-01052" ref-type="bibr">53</xref>] (<xref rid="microorganisms-10-01052-f001" ref-type="fig">Figure 1</xref>). Moreover, extracellular polymeric substances form part of <italic toggle="yes">A. baumannii</italic> biofilms and are composed of poly-&#x003b2;-(1-6)-N-acetylglucosamine and extracellular DNA, providing structural support and intracellular connectors, which allows for biofilm formation under diverse environmental conditions [<xref rid="B6-microorganisms-10-01052" ref-type="bibr">6</xref>]. Biofilm formation and maintenance have also been associated with intracellular communication, mediated by 3&#x02032;,5&#x02032;-cyclic diguanylic acid and quorum sensing, which is facilitated by AtaI autoinducer synthase and the AbaR cognate receptor [<xref rid="B50-microorganisms-10-01052" ref-type="bibr">50</xref>] (<xref rid="microorganisms-10-01052-f001" ref-type="fig">Figure 1</xref>). Additionally, the association or correlation between biofilm formation and antibiotic resistance has been extensively investigated [<xref rid="B54-microorganisms-10-01052" ref-type="bibr">54</xref>,<xref rid="B55-microorganisms-10-01052" ref-type="bibr">55</xref>,<xref rid="B56-microorganisms-10-01052" ref-type="bibr">56</xref>]. For example, Thummeepak et al. [<xref rid="B54-microorganisms-10-01052" ref-type="bibr">54</xref>] investigated the association between biofilm formation, antibiotic resistance phenotype, and virulence genes in clinical <italic toggle="yes">A. baumannii</italic> (<italic toggle="yes">n</italic> = 225) isolates, with 86.2% of the strains characterised as MDR, of which 76.9% were biofilm producers. The biofilm formation genes, <italic toggle="yes">ompA</italic> and <italic toggle="yes">bap</italic> were further linked/associated with the MDR phenotype of the <italic toggle="yes">A. baumannii</italic> isolates.</p></sec><sec id="sec4-microorganisms-10-01052"><title>4. Biological Control Strategies for MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic></title><p>Novel control strategies to combat MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic> are thus urgently required and were mandated by the World Health Organisation during the development of the global priority pathogen list to assist in prioritising the research and development of new and effective antimicrobial treatments [<xref rid="B57-microorganisms-10-01052" ref-type="bibr">57</xref>]. Accordingly, there has been an upsurge in research focusing on biological control strategies to combat bacteria resistance to many commercially available antibiotics, as these approaches are considered environmentally friendly, cost-effective, self-sustaining, highly specific, and result in low resistance frequencies. While biological control strategies, including ribosomally synthesised primary metabolites such as bacteriocins (garvicin KS, nisin, and enterocin-A and -B), have exhibited antimicrobial activity against <italic toggle="yes">A. baumannii</italic> [<xref rid="B58-microorganisms-10-01052" ref-type="bibr">58</xref>,<xref rid="B59-microorganisms-10-01052" ref-type="bibr">59</xref>], the current review will focus on biological control strategies including non-ribosomally synthesised secondary metabolites such as biosurfactants (lipopeptides and glycolipids), predatory bacteria (<italic toggle="yes">B. bacteriovorus</italic>), and bacteriophages.</p><sec id="sec4dot1-microorganisms-10-01052"><title>4.1. Biosurfactants</title><p>Biosurfactants are non-ribosomally synthesised, surface-active secondary metabolites produced by various actively growing microorganisms including bacteria, yeast, and filamentous fungi [<xref rid="B8-microorganisms-10-01052" ref-type="bibr">8</xref>]. Due to their functional properties (stable under various pH, temperature, and ionic fluctuations; biodegradable; low toxicity; display emulsifying and demulsifying capacity), several companies [Allied Carbon Solutions (Sophorolipids), AGAE Technologies (rhamnolipids), Kaneka Corporation (surfactin) and Toyobo (mannosylerythritol lipids)] produce and apply biosurfactants, approved by the United States Food and Drug Administration (US FDA), in various industries such as pharmaceutical/medical, cosmetic, food, petroleum, wastewater treatment, textile, pesticide, biodegradation, and agricultural industries [<xref rid="B60-microorganisms-10-01052" ref-type="bibr">60</xref>]. Particularly lipopeptide and glycolipids are of extreme interest to the pharmaceutical/medical industry, as various classes exhibit broad-spectrum antimicrobial, antibiofilm, and antiadhesive activity [<xref rid="B8-microorganisms-10-01052" ref-type="bibr">8</xref>,<xref rid="B9-microorganisms-10-01052" ref-type="bibr">9</xref>,<xref rid="B10-microorganisms-10-01052" ref-type="bibr">10</xref>]. The chemotherapeutic potential of these metabolites is primarily attributed to the proposed mode of action of lipopeptides and glycolipids, which target the cellular membrane through a detergent-like and/or flip-flop mechanism (transmembrane lipid translocation) [<xref rid="B13-microorganisms-10-01052" ref-type="bibr">13</xref>].</p><p>Therefore, as the mode of action is multimodal, it is hypothesised that the extensive resistome and virulome of A. baumannii would not influence the activity of the biosurfactants, highlighting the potential pharmaceutical and medical application of the secondary metabolites in various in vitro and in vivo applications [<xref rid="B13-microorganisms-10-01052" ref-type="bibr">13</xref>].</p><sec id="sec4dot1dot1-microorganisms-10-01052"><title>4.1.1. Lipopeptide Biosurfactants</title><sec><title>Surfactin</title><p>The antibacterial activity of the lipopeptide surfactin, primarily produced by <italic toggle="yes">Bacillus</italic> spp., has been reported against various Gram-negative bacteria, including MDR and XDR <italic toggle="yes">A. baumannii</italic>. For example, Havenga et al. [<xref rid="B61-microorganisms-10-01052" ref-type="bibr">61</xref>] investigated the susceptibility of MDR and XDR <italic toggle="yes">A. baumannii</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic> (<italic toggle="yes">P. aeruginosa</italic>), <italic toggle="yes">Escherichia coli</italic> (<italic toggle="yes">E. coli</italic>), and <italic toggle="yes">Klebsiella pneumoniae</italic> (<italic toggle="yes">K. pneumoniae</italic>) strains to a crude surfactin extract (containing C<sub>13&#x02013;16</sub> surfactin analogues) produced by <italic toggle="yes">Bacillus amyloliquefaciens</italic> (<italic toggle="yes">B. amyloliquefaciens</italic>) strain ST34. Results indicated that the crude surfactin (C<sub>13&#x02013;16</sub> surfactin analogue) extract (10.00 mg/mL) retained antimicrobial activity against all (100%) <italic toggle="yes">A. baumannii</italic>, <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">E. coli,</italic> and <italic toggle="yes">K. pneumoniae</italic> strains classified as MDR, XDR, and colistin resistant. While limited research is available on the antibiofilm and antiadhesive activity of surfactin against specifically MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic> strains, the antiadhesive and antibiofilm activity against other Gram-negative and Gram-positive bacteria has been demonstrated. For example, Meena et al. [<xref rid="B62-microorganisms-10-01052" ref-type="bibr">62</xref>] observed that purified surfactin (100 &#x000b5;g/mL) obtained from <italic toggle="yes">Bacillus subtilis</italic> (<italic toggle="yes">B. subtilis</italic>) KLP2015 exhibited increased antimicrobial activity against <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">Salmonella enterica</italic> (<italic toggle="yes">S. enterica</italic>), <italic toggle="yes">Staphylococcus aureus</italic> (<italic toggle="yes">S. aureus</italic>), and <italic toggle="yes">E. coli</italic>, with 58.1% and 47.86% antibiofilm activity recorded for <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">Pseudomonas</italic> sp., respectively. The purified surfactin crude extract (100 &#x000b5;g/mL) was further observed to exhibit antitumor activity against five cancer cell lines (HCT-15, Hep2-C, L-132, MCF-7, and NIH/3T3), with increased cytotoxicity recorded against HCT-15 (80.1 &#x000b1; 1.92%) in comparison to the normal HaCaT (31.45 &#x000b1; 2.58%) cell line.</p><p>In addition to the minimal cytotoxic effects exhibited on healthy cell lines, the toxicology of surfactin has been studied using in vivo models [<xref rid="B63-microorganisms-10-01052" ref-type="bibr">63</xref>,<xref rid="B64-microorganisms-10-01052" ref-type="bibr">64</xref>]. Hwang et al. [<xref rid="B64-microorganisms-10-01052" ref-type="bibr">64</xref>] investigated and compared the antibacterial activity of surfactin C and polymyxin B in a murine (ICR mice and Sprague-Dawley (SD) rats) model infected with <italic toggle="yes">E. coli</italic> O111:B4. Overall, survival rates of 53.3%, 73.3%, and 73.3% were recorded at surfactin C concentrations of 5, 10, and 25 mg/kg, respectively, while survival rates of 86.6% were recorded at 1 mg/kg polymyxin B. Although increased survival rates were recorded for the polymyxin B, the compounds have been shown to exhibit adverse effects (neurotoxicity and nephrotoxicity) at 1 to 2 mg/kg, while research has indicated that surfactin only becomes toxic at significantly higher concentrations [LD<sub>50</sub> (50% lethal dose)] of 100 mg/kg [<xref rid="B63-microorganisms-10-01052" ref-type="bibr">63</xref>]. Thus, while additional in vitro and in vivo studies are required to confirm the safety and efficacy of surfactin, current results substantiate the potential use of this metabolite for the treatment of MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic>-associated infections.</p></sec><sec><title>Serrawettin</title><p>The antibacterial activity of the lipopeptide serrawettin, produced by <italic toggle="yes">Serratia</italic> spp., has been reported against various Gram-negative bacteria, including <italic toggle="yes">A. baumannii</italic> [<xref rid="B10-microorganisms-10-01052" ref-type="bibr">10</xref>]. In a study conducted by Clements et al. [<xref rid="B10-microorganisms-10-01052" ref-type="bibr">10</xref>] three <italic toggle="yes">Serratia marcescens</italic> (<italic toggle="yes">S. marcescens</italic>) strains [pigmented 1 (P1); nonpigmented 1 (NP1) and 2 (NP2)] produced crude extracts containing serrawettin W1, serrawettin W2, glucosamine derivative A, and prodigiosin (P1 only). All three crude extracts (P1, NP1, and NP2) exhibited antimicrobial activity (1 mg/mL) against <italic toggle="yes">A. baumannii</italic> ATCC 19606, whereas only the P1 and NP2 crude extracts were effective in inhibiting the clinical XDR <italic toggle="yes">A. baumannii</italic> strain AB 3. In a follow-up study, the antibiofilm and antiadhesive capabilities of the biosurfactants produced by <italic toggle="yes">S. marcescens</italic> P1 and NP1 against <italic toggle="yes">P. aeruginosa</italic> S1 68 and <italic toggle="yes">Enterococcus faecalis</italic> (<italic toggle="yes">E. faecalis</italic>) S1 were demonstrated [<xref rid="B65-microorganisms-10-01052" ref-type="bibr">65</xref>]. At a P1 crude extract concentration of 2.5 and 50 mg/mL and NP1 crude extract concentration of 5 and &#x0003e;50 mg/mL, <italic toggle="yes">P. aeruginosa</italic> S1 68 and <italic toggle="yes">E. faecalis</italic> S1 biofilms (formed on polystyrene) were dislodged and removed, respectively. In addition, an antiadhesive activity of 99.07% and 94.39%, and 95.83% and 93.11%, against <italic toggle="yes">P. aeruginosa</italic> S1 68 and <italic toggle="yes">E. faecalis</italic> S1, respectively, was observed at a P1 and NP1 crude extract concentration of 50 mg/mL.</p><p>Shanks et al. [<xref rid="B66-microorganisms-10-01052" ref-type="bibr">66</xref>] investigated the haemolytic and cytotoxic effect of serratamolides (serrawettin homologues) against red blood cells (from C57BL/6 mice) as well as human bronchial (A549) epithelial cells and human corneal limbal epithelial cells (HCLE) monolayers. The serratamolides exhibited haemolytic activity at a concentration of 1 mg/mL and cytotoxicity towards human bronchial (A549) epithelial cells and HCLE monolayers at 50 &#x000b5;g/mL. While the cytotoxicity results may limit the use of this lipopeptide, Clements et al. [<xref rid="B10-microorganisms-10-01052" ref-type="bibr">10</xref>] showed that the crude extracts (containing serrawettin W1, serrawettin W2, glucosamine derivative A, and prodigiosin) produced by the <italic toggle="yes">S. marcescens</italic> P1, NP1, and NP2 strains, exhibited no haemolytic activity at a concentration of 1 mg/mL. Additional in vitro and in vivo studies are thus required to investigate the safety of serrawettin lipopeptides before the compounds can be implemented for the biological control of MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic>.</p></sec></sec><sec id="sec4dot1dot2-microorganisms-10-01052"><title>4.1.2. Glycolipid Biosurfactants: Rhamnolipids</title><p>The antibacterial activity of glycolipids such as rhamnolipids, produced by various bacterial species, has been demonstrated against several antibiotic-resistant Gram-positive and Gram-negative bacteria. For example, Ndlovu et al. [<xref rid="B8-microorganisms-10-01052" ref-type="bibr">8</xref>] demonstrated the broad-spectrum antimicrobial activity of a rhamnolipid crude extract (1 mg/mL), consisting of congeners of mono- and di-rhamnolipids, produced by <italic toggle="yes">P. aeruginosa</italic> ST5, against antibiotic-resistant Gram-positive and Gram-negative bacteria, including <italic toggle="yes">S. aureus</italic> ATCC 25923, methicillin-resistant <italic toggle="yes">S. aureus</italic> (MRSA) <italic toggle="yes">Xen 30</italic>, <italic toggle="yes">K. pneumoniae</italic> (ATCC 10031, P2, P3, k2a), enteropathogenic <italic toggle="yes">E. coli</italic> B170, <italic toggle="yes">S. enterica,</italic> and <italic toggle="yes">Acinetobacter</italic> sp. F1S6. Moreover, while limited research has been published on the antiadhesive and antibiofilm activity of rhamnolipids against specifically MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic> strains, the antiadhesive, antibiofilm, and cytotoxic activity of rhamnolipids has been demonstrated. Aleksic et al. [<xref rid="B67-microorganisms-10-01052" ref-type="bibr">67</xref>] investigated the antibacterial, antibiofilm, and cytotoxic properties of a di-rhamnolipid (Rha-Rha-C<sub>10</sub>-C<sub>10</sub>, Rha-Rha-C<sub>8</sub>-C<sub>10</sub>, and Rha-Rha-C<sub>10</sub>-C<sub>12</sub>) produced by <italic toggle="yes">Lysinibacillus</italic> sp. BV152.1, which exhibited increased antiadhesive and antibiofilm activity towards <italic toggle="yes">P. aeruginosa</italic> PAO1 (NCTC 10332) biofilms at 50 &#x000b5;g/mL and 75 &#x000b5;g/mL, respectively. Additionally, the authors observed that the rhamnolipid exhibited no cytotoxic activity toward human lung fibroblasts (MRC5) cell lines at a concentration of 100 &#x000b5;g/mL. Thanomsub et al. [<xref rid="B68-microorganisms-10-01052" ref-type="bibr">68</xref>] further reported that rhamnolipids, produced by <italic toggle="yes">P. aeruginosa</italic> B189, exhibited cytotoxic activity against a breast cancer cell line (MCF-7) at a MIC of 6.25 &#x000b5;g/mL, with no toxicity recorded against healthy vero cell lines at the tested concentration range of 0.78 to 50 &#x000b5;g/mL. Tawfeeq and Yesser [<xref rid="B69-microorganisms-10-01052" ref-type="bibr">69</xref>] then provided insight into the in vivo antimicrobial potential of rhamnolipids. Using a murine (<italic toggle="yes">Mus musculus</italic>) model superficially infected with <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">P. aeruginosa</italic>, the authors showed that at a concentration of 30 mg/mL purified PS10 and PS16 rhamnolipid, the infection cleared within 10 to 12 days, in comparison to the untreated mice, where a 17-day recovery period was required. Thus, while the in vivo treatment efficacy of rhamnolipids has been demonstrated, the efficacy of these secondary metabolites against specifically MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic> strains needs to be investigated and validated.</p></sec><sec id="sec4dot1dot3-microorganisms-10-01052"><title>4.1.3. Biosurfactant Applications: Current Limitations and Potential Mitigation Strategies</title><p>While limited research has been published on the resistance of pathogenic Gram-negative bacteria to the various classes of biosurfactants, several studies have been published on mechanisms by which biosurfactant-producing microorganisms may themselves potentially exhibit resistance to this class of secondary metabolites. Research on biosurfactant resistance by the producer strains has almost exclusively been conducted on the lipopeptide surfactin, produced by <italic toggle="yes">B. subtilis</italic>, and has been associated with: (1) RND-like superfamily type efflux system or other proton motive force dependant transporters [YerP (yerP), YcxA (ycxA), and KrsE (krsE)]; (2) biochemical and biophysical membrane alterations ((i) the transient reduction in branched fatty acids; (ii) the emergence of non-branched C<sub>16:00</sub> and C<sub>18:00</sub> fatty acids; (iii) gradual replacement of phosphatidylglycerol and phosphatidylethanolamine with the &#x0201c;stress phospholipid&#x0201d; cardiolipins); and (3) additional enzymatic resistance (hydrolase) (<xref rid="microorganisms-10-01052-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B12-microorganisms-10-01052" ref-type="bibr">12</xref>,<xref rid="B13-microorganisms-10-01052" ref-type="bibr">13</xref>]. Thus, while the self-resistance mechanisms exhibited by the producer strains are diverse and complex, observations made in these mechanistic studies indicate that biosurfactant resistance amongst other bacteria (including <italic toggle="yes">A. baumannii</italic>) may potentially be mediated through an adaptive change in the cell wall or through the production of inactivating enzymes.</p><p>Therefore, to circumvent the potential development of resistance to biosurfactants by the target pathogenic Gram-negative and Gram-positive bacteria, combination therapy could be implemented as studies have reported on the synergistic interaction between biosurfactants and antibiotics [<xref rid="B71-microorganisms-10-01052" ref-type="bibr">71</xref>,<xref rid="B72-microorganisms-10-01052" ref-type="bibr">72</xref>]. For example, Sudarmono et al. [<xref rid="B72-microorganisms-10-01052" ref-type="bibr">72</xref>] investigated the potential synergistic combination of a commercial antibiotic (ampicillin) with surfactin (produced by <italic toggle="yes">B. amyloliquefaciens</italic> MD4-12) against <italic toggle="yes">P. aeruginosa</italic> ATCC 27853. The MIC of surfactin against <italic toggle="yes">P. aeruginosa</italic> ATCC 27853 exceeded 1024 &#x003bc;g/mL, whereas a MIC of 256 &#x003bc;g/mL was recorded for ampicillin. In contrast, the combination of 32 to 512 &#x003bc;g/mL surfactin with 64 &#x003bc;g/mL ampicillin resulted in a greater antimicrobial effect being exhibited against the test organism. Similarly, Samadi et al. [<xref rid="B71-microorganisms-10-01052" ref-type="bibr">71</xref>] demonstrated the combination effect of rhamnolipids (produced by <italic toggle="yes">P. aeruginosa</italic> MN1) with oxacillin against seven <italic toggle="yes">S. aureus</italic> isolates (ATCC 33591 and MRSA1&#x02013;MRSA6). Rhamnolipid and oxacillin MICs ranged from 25 to 50 &#x000b5;g/mL and 50 to 1600 &#x000b5;g/mL, respectively, against the <italic toggle="yes">S. aureus</italic> ATCC 33591 and MRSA1 to MRSA6 isolates. However, in combination experiments with rhamnolipid (6.25&#x02013;25 &#x000b5;g/mL) and oxacillin (0.1&#x02013;6.25 &#x000b5;g/mL), synergism was recorded against MRSA1, MRSA4, and <italic toggle="yes">S. aureus</italic> ATCC 33591, whereas partial synergism was recorded against MRSA2, MRSA3, MRSA5, and MRSA6. Overall, these studies demonstrated the extent to which biosurfactants (lipopeptides and glycolipids) could be used to curtail resistance development and increase or broaden the antimicrobial activity, through the potential re-sensitization of the target bacteria to commercially available antibiotics.</p><p>While it is evident that biosurfactants (lipopeptides and glycolipids) could be applied to the pharmaceutical/medical industry as monotherapies or in combination with commercial antibiotics, the commercialisation or large-scale (up-scaling) production remains a major limitation as the process is not cost-effective. To date, several strategies have thus been proposed to reduce or mitigate the overall cost and increase biosurfactant yield for large-scale production, including (1) the use of low-cost substrates; (2) improvement of medium composition through statistical optimisation; and (3) the genetic engineering of biosurfactant producing bacteria to enhance biosurfactant production [<xref rid="B73-microorganisms-10-01052" ref-type="bibr">73</xref>]. For example, biosurfactant (lipopeptides and glycolipids) production has primarily been carried out in synthetic mediums such as mineral salt medium (MSM) with a carbon source (glucose, sucrose, fructose, or glycerol); however, the use of inexpensive and renewable substrates, including waste products from various industries (food, petroleum, wastewater treatment, and agricultural) are being investigated to reduce the cost associated with large-scale production (extensively reviewed by Banat et al. [<xref rid="B74-microorganisms-10-01052" ref-type="bibr">74</xref>]).</p><p>Growth medium optimisation has also been recommended to improve biosurfactant yield and reduce the cost associated with large-scale production. Two statistical methods, namely, the Plackett&#x02013;Burman design (PBD) and the response surface methodology (RSM) have been extensively implemented to optimise media components for enhancing surfactin and rhamnolipid production. The PBD identifies the most important variables (chemical composition of media, pH, osmolarity, temperature, oxygenation, and agitation) affecting the response (biosurfactant production) for further downstream optimisation. In comparison, RSM is a follow-up statistical method of the PBD and allows for the modelling and collective analysis of all the important variables, with the objective to optimise the response [<xref rid="B75-microorganisms-10-01052" ref-type="bibr">75</xref>]. Wibisana et al. [<xref rid="B76-microorganisms-10-01052" ref-type="bibr">76</xref>] implemented RSM statistical optimisation to screen the significant factors, including production medium components (carbon and nitrogen source, monosodium glutamate, magnesium sulphate, dipotassium phosphate, potassium chloride, and trace elements) and environmental conditions (pH and temperature), which affected surfactin production by <italic toggle="yes">B. amyloliquefaciens</italic> MD4-12. Through the optimisation process, the authors increased <italic toggle="yes">B. amyloliquefaciens</italic> MD4-12 surfactin production by 2.4-fold (1.25 g/L) in comparison to the un-optimised conditions.</p><p>It should, however, be noted that while the implementation of statistical methods has been effective in the optimisation of biosurfactant production, secondary metabolite production may be restricted by the low concentration and productivity of the wild-type bacterial strain [<xref rid="B77-microorganisms-10-01052" ref-type="bibr">77</xref>]. Consequently, research has shifted towards the genetic engineering of bacteria to enhance biosurfactant production. Initial attempts were primarily focused on the generation of random mutations (mutagenesis), which were proposed to result in increased biosurfactant production, through ultra-violet (UV) radiation and <italic toggle="yes">N</italic>-methyl-<italic toggle="yes">N</italic>&#x02019;-nitro-<italic toggle="yes">N</italic>-nitrosoguanidine (NMG) exposure. For example, UV radiation treatment of <italic toggle="yes">B. subtilis</italic> ATCC 21332 resulted in a 3-fold increase in surfactin production in comparison to the wild-type <italic toggle="yes">B. subtilis</italic> ATCC 21332 strain [<xref rid="B78-microorganisms-10-01052" ref-type="bibr">78</xref>]. Similarly, random mutagenesis with NMG was applied to <italic toggle="yes">Bacillus licheniformis</italic> KGL11, resulting in a 12-fold increase in surfactin production [<xref rid="B79-microorganisms-10-01052" ref-type="bibr">79</xref>]. More recently, genetic engineering approaches, such as recombinant DNA technology, the overexpression of extracellular peptides, substitutions, replacement, and modification of amino acids as well as gene/gene cluster knockouts (extensively reviewed by Jimoh et al. [<xref rid="B80-microorganisms-10-01052" ref-type="bibr">80</xref>]), have been implemented to improve biosurfactant production by specific bacterial strains including <italic toggle="yes">Bacillus</italic> and <italic toggle="yes">Pseudomonas</italic> spp. For example, Jung et al. [<xref rid="B81-microorganisms-10-01052" ref-type="bibr">81</xref>] genetically engineered a <italic toggle="yes">B. subtilis</italic> 1012WT to overexpress extracellular peptides, ComX (<italic toggle="yes">comX</italic>) and PhrC (<italic toggle="yes">phrC</italic>), which are associated with the stimulation of surfactin production under low-cell densities. The recombinant <italic toggle="yes">B. subtilis</italic> pHT43-<italic toggle="yes">comXphrC</italic> strain produced 6.4-fold (135.1 mg/L) more surfactin in comparison to the wild-type (1012WT) strain. Genetic engineering could thus be applied to enhance biosurfactant production; however, biosurfactant yield improvement (optimisation) will only be fully realised once the regularity mechanisms of biosurfactant production are fully elucidated [<xref rid="B11-microorganisms-10-01052" ref-type="bibr">11</xref>].</p></sec></sec><sec id="sec4dot2-microorganisms-10-01052"><title>4.2. Predatory Bacteria: Bdellovibrio bacteriovorus</title><p><italic toggle="yes">Bdellovibrio bacteriovorus</italic> is one of the most extensively studied predatory bacteria in the Bdellovibrionaceae family and is characterised by a periplasmic biphasic or dimorphic life cycle. In the attack phase, motile, free-swimming predator cells scavenge or search for prey bacteria. Once the predator attaches to the potential prey, it invades the prey cell forming the bdelloplast (structure in which progeny cells are produced), whereafter it produces various hydrolytic enzymes, which degrade the prey cell components in the growth phase [<xref rid="B82-microorganisms-10-01052" ref-type="bibr">82</xref>]. During the growth phase, bdelloplast formation results in the rounding morphology of the prey cell as a result of peptidoglycan modifications, followed by predator septation and the release of flagellated progeny cells (<xref rid="microorganisms-10-01052-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B82-microorganisms-10-01052" ref-type="bibr">82</xref>,<xref rid="B83-microorganisms-10-01052" ref-type="bibr">83</xref>,<xref rid="B84-microorganisms-10-01052" ref-type="bibr">84</xref>]. As a result of its obligate predatory lifestyle, <italic toggle="yes">B. bacteriovorus</italic> has been investigated as a biocontrol agent in the aquaculture, agriculture, water, and sanitation industries [<xref rid="B15-microorganisms-10-01052" ref-type="bibr">15</xref>].</p><p>Moreover, the application of <italic toggle="yes">B. bacteriovorus</italic> as a live antibiotic in the pharmaceutical and medical industry has gained interest due to the increased prevalence of infections caused by MDR, XDR, and PDR bacteria, including strains of <italic toggle="yes">A. baumannii</italic> [<xref rid="B85-microorganisms-10-01052" ref-type="bibr">85</xref>,<xref rid="B86-microorganisms-10-01052" ref-type="bibr">86</xref>]. Kadouri et al. [<xref rid="B85-microorganisms-10-01052" ref-type="bibr">85</xref>] assessed the predatory efficiency of two <italic toggle="yes">B. bacteriovorus</italic> strains, namely, <italic toggle="yes">B. bacteriovorus</italic> 109J and <italic toggle="yes">B. bacteriovorus</italic> HD100 (ATCC 15356), in co-culture with the MDR Gram-negative pathogens <italic toggle="yes">A. baumannii, E. coli, K. pneumoniae, P. aeruginosa,</italic> and <italic toggle="yes">Pseudomonas putida</italic> (<italic toggle="yes">P. putida</italic>). <italic toggle="yes">Bdellovibrio bacteriovorus</italic> 109J was able to prey on 93% of the host bacterial strains with pronounced predatory activity exhibited towards <italic toggle="yes">A. baumannii</italic> AB276, <italic toggle="yes">K. pneumoniae</italic> AZ1169, and <italic toggle="yes">P. aeruginosa</italic> GB771. Similarly, <italic toggle="yes">B</italic><italic toggle="yes">. bacteriovorus</italic> HD100 was able to prey on 100% of the prey bacteria with significant reductions in cell counts recorded for <italic toggle="yes">A. baumannii</italic> AB276, <italic toggle="yes">E. coli</italic> YD438, <italic toggle="yes">K. pneumoniae</italic> AZ1093, and <italic toggle="yes">P. putida</italic> YA241. Correspondingly, Dharani et al. [<xref rid="B86-microorganisms-10-01052" ref-type="bibr">86</xref>] investigated the predatory efficacy of <italic toggle="yes">B. bacteriovorus</italic> strains (109J and HD100) on planktonic and sessile cultures of colistin sensitive (wild-type) and <italic toggle="yes">mcr-1</italic> positive, colistin-resistant <italic toggle="yes">A. baumannii</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">K. pneumoniae,</italic> and <italic toggle="yes">P. aeruginosa</italic> strains. Based on the results obtained, colistin sensitive and resistant planktonic cultures of the prey bacteria were susceptible to both <italic toggle="yes">B. bacteriovorus</italic> strains 109J and HD100. Moreover, colistin resistance had no significant influence on the antibiofilm activity of the predators, as <italic toggle="yes">B. bacteriovorus</italic> 109J and HD100 reduced the biofilm density of the wild-type <italic toggle="yes">A. baumannii</italic> by 51% and 50%, respectively, which was comparable to the removal of the <italic toggle="yes">mcr-1</italic> positive, colistin-resistant <italic toggle="yes">A. baumannii</italic> biofilm (61% and 57%, respectively).</p><sec><title><italic toggle="yes">Bdellovibrio bacteriovorus</italic> Therapy: Current Limitations and Potential Mitigation Strategies</title><p>While <italic toggle="yes">B. bacteriovorus</italic> resistance has not been detected amongst <italic toggle="yes">A. baumannii</italic> strains, previous studies have observed that certain bacterial species exhibit (1) population-based resistance (plastic phenotypic resistance) and (2) cell-wall based resistance (production of procrystalline protein or S-layer), when exposed to various predatory strains (<xref rid="microorganisms-10-01052-f003" ref-type="fig">Figure 3</xref>) (Shemesh and Jurkevitch 2004). Thus, as <italic toggle="yes">Bdellovibrio</italic> spp. have been observed to exhibit inherent resistance to &#x003b2;-lactam antibiotics and antifolates, it has been hypothesised that <italic toggle="yes">Bdellovibrio</italic> spp. could serve as potentiators or adjuvants to conventional antibiotics (penicillins, carbapenems, and trimethoprim) or antimicrobials, which, in turn, may mitigate the development of predator and/or antibiotic resistance [<xref rid="B82-microorganisms-10-01052" ref-type="bibr">82</xref>,<xref rid="B83-microorganisms-10-01052" ref-type="bibr">83</xref>]. Im et al. [<xref rid="B90-microorganisms-10-01052" ref-type="bibr">90</xref>] demonstrated the antimicrobial efficacy of <italic toggle="yes">B. bacteriovorus</italic> HD100 in combination with violacein (bis-indole pigment derived from <italic toggle="yes">Pseudoduganella violaceinigra</italic> sp. NI28) against Gram-positive and Gram-negative bacteria including MDR <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">Bacillus cereus</italic> (<italic toggle="yes">B. cereus</italic>), <italic toggle="yes">Staphylococcus epidermidis</italic> (<italic toggle="yes">S. epidermidis</italic>), <italic toggle="yes">E. coli</italic>, MDR <italic toggle="yes">K. pneumoniae,</italic> and MDR <italic toggle="yes">A. baumannii</italic> in mono- and dual-culture experiments as well as polymicrobial cultures. Violacein in combination with <italic toggle="yes">B. bacteriovorus</italic> HD100, resulted in a 99.8% reduction in <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">A. baumannii</italic> cell counts, respectively, in the monoculture experiments. In addition, treatment (violacein and <italic toggle="yes">B. bacteriovorus</italic> HD100) of dual cultures of either <italic toggle="yes">A. baumannii</italic> or <italic toggle="yes">K. pneumoniae</italic> with <italic toggle="yes">S. epidermidis</italic>, resulted in an average cell count reduction of 99.3% for each of the pathogens. Moreover, the treatment of a polymicrobial culture consisting of <italic toggle="yes">S. aureus</italic>, <italic toggle="yes">A. baumannii</italic>, <italic toggle="yes">B. cereus,</italic> and <italic toggle="yes">K. pneumoniae</italic>, with violacein and <italic toggle="yes">B. bacteriovorus</italic> HD100, also resulted in a 99.96% cell count reduction. Through the development of a novel liquid assay, Marine et al. [<xref rid="B82-microorganisms-10-01052" ref-type="bibr">82</xref>] proceeded to screen 21 commercial antibiotics in combination with <italic toggle="yes">B. bacteriovorus</italic> HD100. The aim of the study was to determine whether the combination of the commercial antibiotics with the predatory bacterium would produce an increased antimicrobial efficacy and reduce the development of antibiotic resistance. Trimethoprim then exhibited the lowest activity against <italic toggle="yes">B. bacteriovorus</italic> HD100 and highest activity towards <italic toggle="yes">E. coli</italic>, which implied that this antibiotic could potentially be employed in combination therapy with the predatory bacterium. Furthermore, the development of this novel screening method implies that other <italic toggle="yes">B. bacteriovorus</italic> strains could potentially be screened and applied in combination with commercial antibiotics, broadening the antibacterial application of <italic toggle="yes">B. bacteriovorus</italic> and simultaneously circumventing the potential development of predation and antibiotic resistance.</p><p>In addition to predatory resistance, environmental conditions, or factors (viscosity, osmolarity, and temperature) have been identified as a potential limitation for the application of the predatory bacteria as biological control agents [<xref rid="B83-microorganisms-10-01052" ref-type="bibr">83</xref>]. For example, in the study conducted by Im et al. [<xref rid="B91-microorganisms-10-01052" ref-type="bibr">91</xref>], serum albumin and osmolarity (environmental factor) were observed to inhibit <italic toggle="yes">B. bacteriovorus</italic> HD100 predation on <italic toggle="yes">E. coli</italic> MG1655, <italic toggle="yes">K. pneumoniae</italic> (clinical isolate), and <italic toggle="yes">S. enterica</italic> KACC 11595 in a human serum model. Using different concentrations of NaCl [0.65 to 1% (<italic toggle="yes">w</italic>/<italic toggle="yes">v</italic>)] to adjust the osmolarity of the HEPES buffer, the authors observed a reduction in the predation activity of <italic toggle="yes">B. bacteriovorus</italic> HD100 at an osmolarity greater than 200 mOsm/kg (milliosmoles per kilogram) (0.65% NaCl), whereas predation was completely inactivated at 250 mOsm/kg (0.82% NaCl). Stabilisation of the predatory bacterium could, however, be carried out through biopolymeric encapsulation [<xref rid="B92-microorganisms-10-01052" ref-type="bibr">92</xref>]. Cao et al. [<xref rid="B92-microorganisms-10-01052" ref-type="bibr">92</xref>] implemented spray drying to encapsulate <italic toggle="yes">Bdellovibrio</italic> sp. strain F16 in gelatin, allowing the predatory bacterium to remain viable at a concentration of 3.5 &#x000d7; 10<sup>7</sup> plaque-forming units (PFU)/g after 120 days at room temperature. Additionally, the encapsulated <italic toggle="yes">Bdellovibrio</italic> sp. strain F16 retained predatory activity and exhibited antimicrobial activity towards shrimp-pathogenic vibrios at a concentration of 0.8 mg/L. Thus, while the development of bioactive biopolymers for encapsulation of the predator may allow for environmental stabilisation and long-term storage, the implementation of a living bacterium for the treatment of MDR, XDR, and PDR infections may be problematic due to several pharmaceutical and medical legislation and regulations.</p><p>The use of <italic toggle="yes">B. bacteriovorus</italic>-derived enzymes, which have been demonstrated to exhibit antimicrobial and antibiofilm activity, may thus be a more feasible endeavour [<xref rid="B83-microorganisms-10-01052" ref-type="bibr">83</xref>,<xref rid="B93-microorganisms-10-01052" ref-type="bibr">93</xref>]. For example, while <italic toggle="yes">A. baumannii</italic> was not investigated, Monnappa et al. [<xref rid="B93-microorganisms-10-01052" ref-type="bibr">93</xref>] demonstrated the antimicrobial and antibiofilm efficacy of extracellular enzymes (serine proteases Bd1962, Bd2269, carboxypeptidase Bd0306, and DNases) produced by a host-independent (HI) <italic toggle="yes">B. bacteriovorus</italic> HD100 strain against the Gram-positive bacterium <italic toggle="yes">S. aureus</italic> KACC 10768. A 10% volume of cell-free HI <italic toggle="yes">B. bacteriovorus</italic> HD100 spent media or supernatant was capable of disrupting &#x0003e; 75% of the <italic toggle="yes">S. aureus</italic> KACC 10768 biofilm within 24 h. In addition, exposure to the HI <italic toggle="yes">B. bacteriovorus</italic> HD100 supernatant, decreased the virulence-associated features (dispersal of biofilm and decreased invasion of human epithelial (MCF-10a) cells) of <italic toggle="yes">S. aureus</italic> KACC 10768 cells, further highlighting the potential biological control application of the hydrolytic enzyme derived from predatory bacteria. Thus, while research on the stability of <italic toggle="yes">B. bacteriovorus</italic>-derived enzymes is limited, enzyme stabilisation could be implemented through immobilization by physical adsorption, ionic and covalent bonds, and various other techniques such as entrapment, encapsulation, and cross linking [<xref rid="B94-microorganisms-10-01052" ref-type="bibr">94</xref>]. However, for the commercial application of <italic toggle="yes">B. bacteriovorus</italic> or <italic toggle="yes">B. bacteriovorus</italic>-derived enzymes, the large-scale production (or up-scaling) and subsequent downstream processing methods need to be developed and optimised.</p></sec></sec><sec id="sec4dot3-microorganisms-10-01052"><title>4.3. Bacteriophages</title><p>Bacteriophages are bacteria-specific viruses consisting of double-stranded or single-stranded DNA or RNA enclosed within a protein coat. They exhibit either a lytic (virulent) life cycle, where they kill the infected host cells, or a lysogenic (temperate) life cycle, where they integrate into the host genome, or exist as plasmids within the host cell (referred to as a prophage) (<xref rid="microorganisms-10-01052-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B95-microorganisms-10-01052" ref-type="bibr">95</xref>]. Lytic bacteriophages are of particular interest as biological control agents as they are highly host specific allowing for the precise or targeted elimination of bacteria without exhibiting nontarget bacterial interactions [<xref rid="B14-microorganisms-10-01052" ref-type="bibr">14</xref>]. Accordingly, bacteriophage-based biological control products have been approved by the US FDA, Canadian Environmental Protection Agency, and European Food Safety Agency for use in the agricultural and food industries [<xref rid="B96-microorganisms-10-01052" ref-type="bibr">96</xref>].</p><p>In addition, Wintachai et al. [<xref rid="B99-microorganisms-10-01052" ref-type="bibr">99</xref>] observed the antibiofilm activity of a <italic toggle="yes">Siphoviridae</italic> bacteriophage (AB1801) against XDR <italic toggle="yes">A. baumannii.</italic> Results indicated that the AB1801 bacteriophage was capable of inhibiting biofilm formation by 66% (10<sup>8</sup> plaque-forming units (PFU)/well) and reduced preformed biofilms by 70% (10<sup>8</sup> PFU/well) following a 24 hour exposure period. Recently, Jiang et al. [<xref rid="B101-microorganisms-10-01052" ref-type="bibr">101</xref>] demonstrated the efficacy of a <italic toggle="yes">Myoviridae</italic> bacteriophage (Abp9) against PDR <italic toggle="yes">A. baumannii</italic> biofilms, with results indicating a 72.2% biofilm reduction within 2 hours.</p><p>The therapeutic potential of bacteriophages against <italic toggle="yes">A. baumannii</italic> has also been observed in several in vivo studies [<xref rid="B102-microorganisms-10-01052" ref-type="bibr">102</xref>,<xref rid="B103-microorganisms-10-01052" ref-type="bibr">103</xref>]. For example, Jeon et al. [<xref rid="B103-microorganisms-10-01052" ref-type="bibr">103</xref>] investigated and evaluated the in vivo antibacterial potential of two <italic toggle="yes">Myoviridae</italic> bacteriophages (YMC 13/03/R2096 ABA BP or &#x00392;&#x003d5;-R2096) in two animal models [larva (<italic toggle="yes">G. mellonella</italic>) and murine (C57BL/6 mice)] infected with carbapenem-resistant <italic toggle="yes">A. baumannii.</italic></p><p>Administration of the &#x00392;&#x003d5;-R2096 bacteriophage to the larva (<italic toggle="yes">G. mellonella</italic>) model infected with <italic toggle="yes">A. baumannii</italic>, resulted in a 50% increased survival rate within 24 hours (post-infection), whereas the bacteriophage administered to the murine (C57BL/6 mice) model increased survival from 30% (multiplicity of infection; MOI = 0.1) to 100% (MOI = 10) within 12 days. In addition, the administration of &#x00392;&#x003d5;-R2096 to a murine (C57BL/6 mice) model infected with <italic toggle="yes">A. baumannii</italic> resulted in bacterial clearance within 3 days (post-infection) with no mortality or deleterious side effects observed. Moreover, Hua et al. [<xref rid="B102-microorganisms-10-01052" ref-type="bibr">102</xref>] observed that a <italic toggle="yes">Podoviridae</italic> bacteriophage (SH-Ab15519) exhibited antibacterial activity at a lower titre (or MOI) during the treatment of a murine (BALB/c mice) model infected with carbapenem-resistant <italic toggle="yes">A. baumannii</italic>. Overall, a 90% survival rate was recorded at an MOI of 0.1, 1, and 10, in comparison to the 10% survival rate recorded for the non-bacteriophage-treated control group, with no adverse side effects detected.</p><p>While reports are limited, bacteriophage therapies have been implemented for the treatment of human <italic toggle="yes">A. baumannii</italic> infections, in cases where all other therapeutic options were exhausted [<xref rid="B104-microorganisms-10-01052" ref-type="bibr">104</xref>,<xref rid="B105-microorganisms-10-01052" ref-type="bibr">105</xref>]. Recently, Tan et al. [<xref rid="B104-microorganisms-10-01052" ref-type="bibr">104</xref>] administered a single-bacteriophage preparation to an 88-year-old patient suffering from chronic obstructive pulmonary disease (lung disease) and type-2 diabetes, who developed hospital-acquired pneumonia (mechanical ventilation associated) caused by carbapenem-resistant <italic toggle="yes">A. baumannii</italic>. Following the administration (viz., nebulisation) of the single Ab_SZ3 (<italic toggle="yes">Siphoviridae</italic>) bacteriophage preparation for 16 days, clearance of the carbapenem-resistant <italic toggle="yes">A. baumannii</italic> was observed with no reappearance recorded. In addition, during the ongoing coronavirus disease 2019 (COVID-19) pandemic, Wu et al. [<xref rid="B105-microorganisms-10-01052" ref-type="bibr">105</xref>] implemented compassionate bacteriophage therapy for the treatment of patients (<italic toggle="yes">n</italic> = 4) suffering from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) complicated with carbapenem-resistant <italic toggle="yes">A. baumannii</italic> lung infections. A single bacteriophage (&#x02205;Ab121) was administered to one patient (patient 1); however, following treatment (viz., nebulisation) bacteriophage resistance was observed. Thereafter, a combination of two pre-optimised bacteriophages (&#x02205;Ab121 and &#x02205;Ab124) were administered to the four patients through nebulisation (patient 1 to 4) and topical applications (patient 3). Bacteriophage therapy in patients 1 and 2 resulted in infection clearance, recovery, and hospital discharge. However, while biological clearance of MDR <italic toggle="yes">A. baumannii</italic> was observed in patients 3 and 4, both patients died due to respiratory failure, with patient 3 also infected with a carbapenem-resistant <italic toggle="yes">K. pneumoniae</italic> infection.</p><sec><title>Bacteriophage Therapy: Current Limitations and Potential Mitigations Strategies</title><p>While bacteriophage-based therapies hold immense potential as biological control agents; the emergence of bacteriophage resistance mediated via: (1) receptor adaptations (mutations of phenotypical alteration resulting in decreased bacteriophage adsorption); (2) host defence systems (molecular pathways preventing or suppressing phage infections); and (3) phage-derived defence systems (molecular pathways facilitating bacterial competition of host), remains a major obstacle, hampering the effective application of this treatment (<xref rid="microorganisms-10-01052-f004" ref-type="fig">Figure 4</xref>) (extensively reviewed by Egido et al. [<xref rid="B98-microorganisms-10-01052" ref-type="bibr">98</xref>]). The underlying resistance mechanisms have subsequently been identified and exploited in an approach referred to as &#x0201c;bacteriophage steering&#x0201d;, which involves the &#x0201c;exploitation-specific fitness trade-offs&#x0201d; associated with bacteriophage resistance, including antimicrobial re-sensitisation, reduced virulence, and colonisation defects [<xref rid="B106-microorganisms-10-01052" ref-type="bibr">106</xref>,<xref rid="B107-microorganisms-10-01052" ref-type="bibr">107</xref>]. For example, Altamirano et al. [<xref rid="B106-microorganisms-10-01052" ref-type="bibr">106</xref>] isolated a <italic toggle="yes">Myoviridae</italic> bacteriophage (&#x00278;FG02) and an <italic toggle="yes">Ackermannviridae</italic> bacteriophage (&#x00278;CO01). Following co-culturing with the respective <italic toggle="yes">A. baumannii</italic> host strains, bacteriophage resistance was observed, which correlated with the loss of the CPS. Several exploitable fitness trade-offs were, however, subsequently identified, including reduced <italic toggle="yes">A. baumannii</italic> biofilm formation on polystyrene, reduced virulence in a murine (BALB/c mice) model, re-sensitisation to the human complement system as well as alternative bacteriophages (bacteriophages from different families) and antibiotics (&#x003b2;-lactams and fluoroquinolones). Similarly, Wang et al. [<xref rid="B107-microorganisms-10-01052" ref-type="bibr">107</xref>] observed that a colistin-resistant <italic toggle="yes">A. baumannii</italic> ATCC 17978 exhibited resistance to a <italic toggle="yes">Myoviridae</italic> bacteriophage (Phab24) following co-culturing. Bacteriophage resistance was subsequently attributed to LPS (<italic toggle="yes">lpsBSP</italic>) and capsule polysaccharide (amylovoran: <italic toggle="yes">amsE</italic>) biosynthesis alterations. The bacteriophage-resistant <italic toggle="yes">A. baumannii</italic> isolates then exhibited several exploitable fitness trade-offs including decreased in vivo virulence in a larva (<italic toggle="yes">G. mellonella</italic>) model and increased colistin re-sensitisation.</p><p>Bacteriophage&#x02013;antibiotic combinations have also been highlighted as a promising approach to reduce bacteriophage resistance [<xref rid="B106-microorganisms-10-01052" ref-type="bibr">106</xref>]. The increased antibacterial activity of bacteriophage&#x02013;antibiotic combinations is based on the phenomenon referred to as bacteriophage&#x02013;antibiotic synergy or phage&#x02013;antibiotic synergy (PAS) (extensively reviewed by Segall et al. [<xref rid="B108-microorganisms-10-01052" ref-type="bibr">108</xref>]). Bacteriophage&#x02013;antibiotic synergy has only recently been demonstrated against MDR <italic toggle="yes">A. baumannii</italic>, with Grygorcewicz et al. [<xref rid="B109-microorganisms-10-01052" ref-type="bibr">109</xref>] investigating a bacteriophage cocktail (five bacteriophages) in combination with 10 antibiotics as an antibiofilm strategy. Overall, the combination of the five bacteriophages with 0.25 mg/mL and 0.5 mg/L trimethoprim&#x02013;sulfamethoxazole, resulted in the highest biofilm biomass reduction of 94.3% and 98.6%, respectively. Additionally, Grygorcewicz et al. [<xref rid="B110-microorganisms-10-01052" ref-type="bibr">110</xref>] investigated the efficacy of the vB_AbaP_AGC01 bacteriophage (<italic toggle="yes">Autographivirinae</italic>) in combination with several antibiotics (ciprofloxacin, gentamicin, and meropenem) against <italic toggle="yes">A. baumannii</italic> ATCC 19606. A synergistic interaction was observed during the combination of bacteriophage AGC01 (MOI = 10) with meropenem (20 mg/L) and ciprofloxacin (10 mg/L) leading to a 99.99% reduction in <italic toggle="yes">A. baumannii</italic> ATCC 19606 cell counts. The antimicrobial activity of the AHC01&#x02013;antibiotic combination was further investigated using the in vivo larva (<italic toggle="yes">G. mellonella</italic>) model, with the AHC01&#x02013;meropenem combination resulting in increased larval survival, with a rate of 35% to 77% recorded in comparison to the bacteriophage only control. The PAS phenomenon further validates the use of bacteriophages as a biological control agent against MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic>; however, additional studies are required to investigate the mode of action as the PAS may be strain specific.</p><p>Resistance development could potentially be circumvented using bacteriophage-derived enzymes as the compounds have been shown to exhibit both in vitro and in vivo antimicrobial activity [<xref rid="B111-microorganisms-10-01052" ref-type="bibr">111</xref>,<xref rid="B112-microorganisms-10-01052" ref-type="bibr">112</xref>]. For example, Kim et al. [<xref rid="B112-microorganisms-10-01052" ref-type="bibr">112</xref>] demonstrated the antimicrobial activity of LysSS, a novel phage endolysin (also termed bacteriophage lysins or enzybiotics), against 16 MDR <italic toggle="yes">A. baumannii</italic> strains. Overall, LysSS exhibited antimicrobial activity at a MIC of 0.063 to 0.25 mg/mL against the MDR <italic toggle="yes">A. baumannii</italic> strains. In addition, LysSS exhibited no in vivo cytotoxic effect on human lung (A549) cells below 250 &#x000b5;g/mL. The administration of 125 &#x000b5;g/mL LysSS also resulted in a 40% survival rate in a murine (BALB/c mice) model infected with <italic toggle="yes">A. baumannii</italic>. In addition, endolysins have been combined with commercially available antibiotics for the in vitro and in vivo treatment of <italic toggle="yes">A. baumannii</italic>-associated infections. Blasco et al. [<xref rid="B111-microorganisms-10-01052" ref-type="bibr">111</xref>] combined the endolysin ElyA1 (25 &#x000b5;g/mL) with colistin, which resulted in a fourfold reduction in the colistin MIC against clinical <italic toggle="yes">A. baumannii</italic> strains (<italic toggle="yes">n</italic> = 25). The results were further confirmed in three in vitro assays using larva (<italic toggle="yes">G. mellonella</italic>), murine (BALB/c mice) skin, and lung infection models.</p><p>Although the bacteriophage-derived enzymes have been observed to exhibit in vitro and in vivo antimicrobial activity, additional fundamental research is required to investigate environmental stability (temperature, pH, osmolarity, and UV) as fluctuations may influence the biologic control applications. Enzyme stabilisation could be facilitated through the selection of optimal conditions [enzyme concentration, storage buffer, pH, temperature, and the addition of chemical stabilisers (calcium ions and Poloxamer 188)] [<xref rid="B113-microorganisms-10-01052" ref-type="bibr">113</xref>,<xref rid="B114-microorganisms-10-01052" ref-type="bibr">114</xref>]. Bacteriophage endolysins produced in native form often exhibit poor expression or insolubility; therefore, Jun et al. [<xref rid="B113-microorganisms-10-01052" ref-type="bibr">113</xref>] stabilised the recombinant SAL-1 (bacteriophage endolysin) with calcium ions and Poloxamer 188 (stabilised endolysin referred to as SAL200) and subsequently evaluated the in vitro and in vivo antibacterial activity against various <italic toggle="yes">S. aureus</italic> strains. Overall, SAL200 retained in vitro bactericidal activity against both planktonic (0.13 &#x000b1; 0.03 &#x000b5;g/mL) and sessile (10 &#x000b5;g/mL) <italic toggle="yes">S. aureus</italic> SA1 cultures. In addition, SAL200 was observed to exhibit broad-spectrum antimicrobial activity against various clinical <italic toggle="yes">S. aureus</italic> isolates (<italic toggle="yes">n</italic> = 425). Moreover, SAL200 retained in vivo activity, as murine (ICR mice) models injected with <italic toggle="yes">S. aureus</italic> SA2 (1 &#x000d7; 10<sup>8</sup> CFU/mouse) remained viable (0% mortality rate: 0/15) at a concentration of 25 mg/kg.</p><p>In addition to chemical stabilisation, molecular engineering has been implemented to stabilise thermo-susceptible endolysins as these enzymes have been observed to exhibit a short-term therapeutic shelf-life expectancy, which may limit the development of potential antimicrobial (enzybiotic) compounds [<xref rid="B114-microorganisms-10-01052" ref-type="bibr">114</xref>]. Therefore, to address the limitations regarding transient long-term stability, Heselpoth et al. [<xref rid="B114-microorganisms-10-01052" ref-type="bibr">114</xref>] implemented a FoldX-driven computational protein engineering to increase the thermostability of the PlyC endolysin (derived from the streptococcal C1 lytic phase) catalytic subunit (PlyCA). Through the implementation of computational engineering and visual inspection, eight-point mutations of the PlyC were identified and predicted to be associated with thermostability. One mutation, PlyC (plyCA) T406R, was shown to experimentally increase the thermal denaturation temperature by ~2.2 &#x000b0;C and kinetic stability by 16-fold in comparison to the wild-type endolysin. While the increase in thermal denaturation was modest, the authors highlighted that a single mutation resulted in a pronounced increase (16-fold) in kinetic stability; therefore, multiple advantageous mutations could be induced to additively stabilise an enzyme for antimicrobial applications.</p><p>While several different bacteriophage-based products (EcoShield&#x02122;, ListShield&#x02122;, and SalmoFresh&#x02122;) have been commercialised, the development of an effective, constant, and controllable process for large-scale bacteriophage production needs to be optimised. Upscaling has primarily been limited due to the biological nature of the system (growth conditions of host bacterium and bacteriophage infection) and the diverse range of interactions described between bacteriophages and bacteria (bacteriophage resistance mechanisms) (reviewed by Garc&#x000ed;a et al. [<xref rid="B115-microorganisms-10-01052" ref-type="bibr">115</xref>]). Several research groups have, however, successfully implemented bioreactors (batch, continuous, or cellstat fermenters) to up-scale bacteriophage production [<xref rid="B116-microorganisms-10-01052" ref-type="bibr">116</xref>,<xref rid="B117-microorganisms-10-01052" ref-type="bibr">117</xref>]. Sochocka et al. [<xref rid="B116-microorganisms-10-01052" ref-type="bibr">116</xref>] successfully implemented a batch (fix volume of nutrients) bioreactor (5 L) to up-scale the production of a T4 bacteriophage using <italic toggle="yes">E. coli</italic> B strain as a bacterial host. Following co-culturing of the T4 bacteriophage and <italic toggle="yes">E. coli</italic> B strain for 24 hours, a bacteriophage titre of 1.2 &#x000d7; 10<sup>16</sup> PFU/mL was obtained. Comparable results were obtained in a study conducted by Warner et al. [<xref rid="B118-microorganisms-10-01052" ref-type="bibr">118</xref>], where the M13 bacteriophage was produced at a titre of 5.0 &#x000d7; 10<sup>12</sup> PFU/mL following batch fermentation with XL1-Blue MRF <italic toggle="yes">E. coli</italic>. While batch fermentation is cost effective, it is limited by the volume of the bioreactor equipment, total operation time, and nutrient availability [<xref rid="B115-microorganisms-10-01052" ref-type="bibr">115</xref>]. Therefore, continuous cultivation (constant influx and efflux of nutrients and waste) has been investigated as an alternative for the upscaling of bacteriophage production. Nabergoj et al. [<xref rid="B117-microorganisms-10-01052" ref-type="bibr">117</xref>] achieved a constant T4 bacteriophage titre of 10<sup>9</sup> bacteriophages per hour in a 1 L cellstat (two bioreactors connected in series) using the bacterial host strain <italic toggle="yes">E. coli</italic> K-12. Furthermore, continuous cultivation systems (chemstat) prevent bacteriophage resistance from developing as two separate bioreactors are used for the growth of bacteria and bacteriophages [<xref rid="B115-microorganisms-10-01052" ref-type="bibr">115</xref>].</p></sec></sec></sec><sec sec-type="conclusions" id="sec5-microorganisms-10-01052"><title>5. Conclusions and Future Research</title><p>The extensive resistome and virulome of the superbug <italic toggle="yes">A. baumannii</italic>, facilitate its survival, proliferation, and epidemic spread in healthcare facilities worldwide. The implementation of biological control strategies including biosurfactants [lipopeptides (surfactin and serrawettin) and glycolipids (rhamnolipids)], predatory bacteria (<italic toggle="yes">B. bacteriovorus</italic>), and bacteriophages could thus potentially be the &#x0201c;silver bullet&#x0201d; solution to combat antibiotic resistance. However, while the antimicrobial activity of biosurfactants, such as surfactin, serrawettin, and rhamnolipids, has been extensively demonstrated against Gram-negative and Gram-positive bacteria, the antiadhesive and antibiofilm activity against MDR, XDR, and PDR <italic toggle="yes">A. baumannii</italic> strains has not been extensively investigated. In addition, fundamental research into potential biosurfactant resistance development as well as the efficacy and safety of these secondary metabolites needs to be conducted using non-mammalian and mammalian models. Moreover, as biosurfactants have been earmarked for their potential pharmaceutical/medical value, research into media optimisation for implementation in cost-effective large-scale production systems (up-scaling) and the application of genetically enhanced producer strains, is required.</p><p>While the predatory bacterium <italic toggle="yes">B. bacteriovorus</italic> has been shown to exhibit antimicrobial and antibiofilm activity towards <italic toggle="yes">A. baumannii</italic> in vitro, future studies should investigate the predator&#x02013;host interaction and host immune response, which would allow for further validation on the safety, functionality, and stability of this biological control strategy. Current research additionally indicates that <italic toggle="yes">B. bacteriovorus</italic> could be used in combination with commercial antibiotics, which may facilitate the re-sensitisation of bacteria to antibiotics, enhance (or broaden) the activity of available antibiotics, and potentially prevent predation resistance development. Furthermore, using bioinformatical analysis and modern genetic engineering approaches, the genes involved in <italic toggle="yes">B. bacteriovorus</italic>-derived enzyme synthesis could be identified, cloned, expressed, and purified for their potential pharmaceutical/medical application.</p><p>Similarly, bacteriophages have been observed to exhibit antimicrobial and antibiofilm activity against <italic toggle="yes">A. baumannii</italic>; however, resistance development is frequently detected. Strategies such as &#x0201c;bacteriophage steering&#x0201d; have thus garnered interest as it allows for antibiotic re-sensitisation and virulence reduction. In addition, bacteriophage&#x02013;antibiotic combinations have been observed to exhibit PAS which could mitigate or prevent resistance development. However, fundamental research into PAS is required as the phenomenon has been reported to be strain specific, which may limit the safety and functionality of the treatment strategy. Bacteriophage-derived enzymes have also been shown to exhibit antibacterial and antibiofilm activity, and research into the stabilisation of the compounds under various environmental conditions (temperature, pH, osmolarity, and UV) is required. This may allow for the development of antimicrobial therapies that remain active during long-term storage and under unfavourable conditions.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, B.H. and W.K.; Writing&#x02014;Original Draft Preparation, B.H.; Writing&#x02014;Review and Editing, B.H., W.K., B.R., M.W.-R., T.N. and S.K. Funding acquisition, W.K. and S.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-microorganisms-10-01052"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gordon</surname><given-names>N.C.</given-names></name>
<name><surname>Wareham</surname><given-names>D.W.</given-names></name>
</person-group><article-title>Multidrug-resistant <italic toggle="yes">Acinetobacter baumannii</italic>: Mechanisms of virulence and resistance</article-title><source>Int. J. Antimicrob. Agents</source><year>2010</year><volume>35</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2009.10.024</pub-id><?supplied-pmid 20047818?><pub-id pub-id-type="pmid">20047818</pub-id></element-citation></ref><ref id="B2-microorganisms-10-01052"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Piperaki</surname><given-names>E.T.</given-names></name>
<name><surname>Tzouvelekis</surname><given-names>L.S.</given-names></name>
<name><surname>Miriagou</surname><given-names>V.</given-names></name>
<name><surname>Daikos</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Carbapenem-resistant <italic toggle="yes">Acinetobacter baumannii</italic>: In pursuit of an effective treatment</article-title><source>Clin. Microbiol. Infect.</source><year>2019</year><volume>25</volume><fpage>951</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2019.03.014</pub-id><?supplied-pmid 30914347?><pub-id pub-id-type="pmid">30914347</pub-id></element-citation></ref><ref id="B3-microorganisms-10-01052"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>C.</given-names></name>
<name><surname>McClean</surname><given-names>S.</given-names></name>
</person-group><article-title>Mapping global prevalence of <italic toggle="yes">Acinetobacter baumannii</italic> and recent vaccine development to tackle it</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>570</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9060570</pub-id><?supplied-pmid 34205838?><pub-id pub-id-type="pmid">34205838</pub-id></element-citation></ref><ref id="B4-microorganisms-10-01052"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Merabishvili</surname><given-names>M.</given-names></name>
<name><surname>Vandenheuvel</surname><given-names>D.</given-names></name>
<name><surname>Kropinski</surname><given-names>A.M.</given-names></name>
<name><surname>Mast</surname><given-names>J.</given-names></name>
<name><surname>De Vos</surname><given-names>D.</given-names></name>
<name><surname>Verbeken</surname><given-names>G.</given-names></name>
<name><surname>Noben</surname><given-names>J.P.</given-names></name>
<name><surname>Lavigne</surname><given-names>R.</given-names></name>
<name><surname>Vaneechoutte</surname><given-names>M.</given-names></name>
<name><surname>Pirnay</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Characterization of newly isolated lytic bacteriophages active against <italic toggle="yes">Acinetobacter baumannii</italic></article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e104853</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0104853</pub-id><pub-id pub-id-type="pmid">25111143</pub-id></element-citation></ref><ref id="B5-microorganisms-10-01052"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savoldi</surname><given-names>A.</given-names></name>
<name><surname>Carrara</surname><given-names>E.</given-names></name>
<name><surname>Piddock</surname><given-names>L.J.</given-names></name>
<name><surname>Franceschi</surname><given-names>F.</given-names></name>
<name><surname>Ellis</surname><given-names>S.</given-names></name>
<name><surname>Chiamenti</surname><given-names>M.</given-names></name>
<name><surname>Bragantini</surname><given-names>D.</given-names></name>
<name><surname>Righi</surname><given-names>E.</given-names></name>
<name><surname>Tacconelli</surname><given-names>E.</given-names></name>
</person-group><article-title>The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: A systematic review of clinical studies</article-title><source>BMC Infect. Dis.</source><year>2021</year><volume>21</volume><elocation-id>545</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-021-06253-x</pub-id><?supplied-pmid 34107899?><pub-id pub-id-type="pmid">34107899</pub-id></element-citation></ref><ref id="B6-microorganisms-10-01052"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mea</surname><given-names>H.J.</given-names></name>
<name><surname>Yong</surname><given-names>P.V.C.</given-names></name>
<name><surname>Wong</surname><given-names>E.H.</given-names></name>
</person-group><article-title>An overview of <italic toggle="yes">Acinetobacter baumannii</italic> pathogenesis: Motility, adherence and biofilm formation</article-title><source>Microbiol. Res.</source><year>2021</year><volume>247</volume><elocation-id>126722</elocation-id><pub-id pub-id-type="doi">10.1016/j.micres.2021.126722</pub-id><pub-id pub-id-type="pmid">33618061</pub-id></element-citation></ref><ref id="B7-microorganisms-10-01052"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drakontis</surname><given-names>C.E.</given-names></name>
<name><surname>Amin</surname><given-names>S.</given-names></name>
</person-group><article-title>Biosurfactants: Formulations, properties, and applications</article-title><source>Curr. Opin. Colloid Interface Sci.</source><year>2020</year><volume>48</volume><fpage>77</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.cocis.2020.03.013</pub-id></element-citation></ref><ref id="B8-microorganisms-10-01052"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ndlovu</surname><given-names>T.</given-names></name>
<name><surname>Rautenbach</surname><given-names>M.</given-names></name>
<name><surname>Vosloo</surname><given-names>J.A.</given-names></name>
<name><surname>Khan</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>W.</given-names></name>
</person-group><article-title>Characterisation and antimicrobial activity of biosurfactant extracts produced by <italic toggle="yes">Bacillus amyloliquefaciens</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic> isolated from a wastewater treatment plant</article-title><source>AMB Express</source><year>2017</year><volume>7</volume><fpage>108</fpage><pub-id pub-id-type="doi">10.1186/s13568-017-0363-8</pub-id><pub-id pub-id-type="pmid">28571306</pub-id></element-citation></ref><ref id="B9-microorganisms-10-01052"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clements</surname><given-names>T.</given-names></name>
<name><surname>Ndlovu</surname><given-names>T.</given-names></name>
<name><surname>Khan</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>W.</given-names></name>
</person-group><article-title>Biosurfactants produced by <italic toggle="yes">Serratia</italic> species: Classification, biosynthesis, production and application</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2019</year><volume>103</volume><fpage>589</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-9520-5</pub-id><pub-id pub-id-type="pmid">30456577</pub-id></element-citation></ref><ref id="B10-microorganisms-10-01052"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clements</surname><given-names>T.</given-names></name>
<name><surname>Ndlovu</surname><given-names>T.</given-names></name>
<name><surname>Khan</surname><given-names>W.</given-names></name>
</person-group><article-title>Broad-spectrum antimicrobial activity of secondary metabolites produced by <italic toggle="yes">Serratia marcescens</italic> strains</article-title><source>Microbiol. Res.</source><year>2019</year><volume>229</volume><elocation-id>126329</elocation-id><pub-id pub-id-type="doi">10.1016/j.micres.2019.126329</pub-id><pub-id pub-id-type="pmid">31518853</pub-id></element-citation></ref><ref id="B11-microorganisms-10-01052"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banat</surname><given-names>I.M.</given-names></name>
<name><surname>Franzetti</surname><given-names>A.</given-names></name>
<name><surname>Gandolfi</surname><given-names>I.</given-names></name>
<name><surname>Bestetti</surname><given-names>G.</given-names></name>
<name><surname>Martinotti</surname><given-names>M.G.</given-names></name>
<name><surname>Fracchia</surname><given-names>L.</given-names></name>
<name><surname>Smyth</surname><given-names>T.J.</given-names></name>
<name><surname>Marchant</surname><given-names>R.</given-names></name>
</person-group><article-title>Microbial biosurfactants production, applications and future potential</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2010</year><volume>87</volume><fpage>427</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1007/s00253-010-2589-0</pub-id><?supplied-pmid 20424836?><pub-id pub-id-type="pmid">20424836</pub-id></element-citation></ref><ref id="B12-microorganisms-10-01052"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Shen</surname><given-names>Z.</given-names></name>
</person-group><article-title>Overexpression of specific proton motive force-dependent transporters facilitate the export of surfactin in <italic toggle="yes">Bacillus subtilis</italic></article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2015</year><volume>42</volume><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1007/s10295-014-1527-z</pub-id><?supplied-pmid 25366377?><pub-id pub-id-type="pmid">25366377</pub-id></element-citation></ref><ref id="B13-microorganisms-10-01052"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinkas</surname><given-names>D.</given-names></name>
<name><surname>Fi&#x00161;er</surname><given-names>R.</given-names></name>
<name><surname>Kozlik</surname><given-names>P.</given-names></name>
<name><surname>Dolej&#x00161;ov&#x000e1;</surname><given-names>T.</given-names></name>
<name><surname>Hryz&#x000e1;kov&#x000e1;</surname><given-names>K.</given-names></name>
<name><surname>Konop&#x000e1;sek</surname><given-names>I.</given-names></name>
<name><surname>Miku&#x00161;ov&#x000e1;</surname><given-names>G.</given-names></name>
</person-group><article-title><italic toggle="yes">Bacillus subtilis</italic> cardiolipin protects its own membrane against surfactin-induced permeabilization</article-title><source>Biochim. Biophys. Acta Biomembr.</source><year>2020</year><volume>1862</volume><elocation-id>183405</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbamem.2020.183405</pub-id><?supplied-pmid 32593615?><pub-id pub-id-type="pmid">32593615</pub-id></element-citation></ref><ref id="B14-microorganisms-10-01052"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Furfaro</surname><given-names>L.L.</given-names></name>
<name><surname>Payne</surname><given-names>M.S.</given-names></name>
<name><surname>Chang</surname><given-names>B.J.</given-names></name>
</person-group><article-title>Bacteriophage therapy: Clinical trials and regulatory hurdles</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2018</year><volume>8</volume><elocation-id>376</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2018.00376</pub-id><?supplied-pmid 30406049?><pub-id pub-id-type="pmid">30406049</pub-id></element-citation></ref><ref id="B15-microorganisms-10-01052"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waso</surname><given-names>M.</given-names></name>
<name><surname>Reyneke</surname><given-names>B.</given-names></name>
<name><surname>Havenga</surname><given-names>B.</given-names></name>
<name><surname>Khan</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>W.</given-names></name>
</person-group><article-title>Insights into <italic toggle="yes">Bdellovibrio</italic> spp. mechanisms of action and potential applications</article-title><source>World J. Microbiol Biotechnol.</source><year>2021</year><volume>37</volume><fpage>85</fpage><pub-id pub-id-type="doi">10.1007/s11274-021-03054-x</pub-id><?supplied-pmid 33860852?><pub-id pub-id-type="pmid">33860852</pub-id></element-citation></ref><ref id="B16-microorganisms-10-01052"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harding</surname><given-names>C.M.</given-names></name>
<name><surname>Hennon</surname><given-names>S.W.</given-names></name>
<name><surname>Feldman</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Uncovering the mechanisms of <italic toggle="yes">Acinetobacter baumannii</italic> virulence</article-title><source>Nat. Rev. Microbiol.</source><year>2018</year><volume>16</volume><fpage>91</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2017.148</pub-id><pub-id pub-id-type="pmid">29249812</pub-id></element-citation></ref><ref id="B17-microorganisms-10-01052"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>C.R.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Park</surname><given-names>M.</given-names></name>
<name><surname>Park</surname><given-names>K.S.</given-names></name>
<name><surname>Bae</surname><given-names>I.K.</given-names></name>
<name><surname>Kim</surname><given-names>Y.B.</given-names></name>
<name><surname>Cha</surname><given-names>C.J.</given-names></name>
<name><surname>Jeong</surname><given-names>B.C.</given-names></name>
<name><surname>Lee</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Biology of <italic toggle="yes">Acinetobacter baumannii</italic>: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2017</year><volume>7</volume><elocation-id>55</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2017.00055</pub-id><pub-id pub-id-type="pmid">28348979</pub-id></element-citation></ref><ref id="B18-microorganisms-10-01052"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magiorakos</surname><given-names>A.P.</given-names></name>
<name><surname>Srinivasan</surname><given-names>A.</given-names></name>
<name><surname>Carey</surname><given-names>R.B.</given-names></name>
<name><surname>Carmeli</surname><given-names>Y.</given-names></name>
<name><surname>Falagas</surname><given-names>M.E.</given-names></name>
<name><surname>Giske</surname><given-names>C.G.</given-names></name>
<name><surname>Harbarth</surname><given-names>S.</given-names></name>
<name><surname>Hindler</surname><given-names>J.F.</given-names></name>
<name><surname>Kahlmeter</surname><given-names>G.</given-names></name>
<name><surname>Olsson-Liljequist</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance</article-title><source>Clin. Microbiol. Infect.</source><year>2012</year><volume>18</volume><fpage>268</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03570.x</pub-id><pub-id pub-id-type="pmid">21793988</pub-id></element-citation></ref><ref id="B19-microorganisms-10-01052"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lowe</surname><given-names>M.</given-names></name>
<name><surname>Ehlers</surname><given-names>M.M.</given-names></name>
<name><surname>Ismail</surname><given-names>F.</given-names></name>
<name><surname>Peirano</surname><given-names>G.</given-names></name>
<name><surname>Becker</surname><given-names>P.J.</given-names></name>
<name><surname>Pitout</surname><given-names>J.D.</given-names></name>
<name><surname>Kock</surname><given-names>M.M.</given-names></name>
</person-group><article-title><italic toggle="yes">Acinetobacter baumannii</italic>: Epidemiological and beta-lactamase data from two tertiary academic hospitals in Tshwane, South Africa</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><elocation-id>1280</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.01280</pub-id><pub-id pub-id-type="pmid">29946315</pub-id></element-citation></ref><ref id="B20-microorganisms-10-01052"><label>20.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2021</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/i/item/9789240027336" ext-link-type="uri">https://www.who.int/publications/i/item/9789240027336</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-01">(accessed on 1 January 2021)</date-in-citation></element-citation></ref><ref id="B21-microorganisms-10-01052"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peleg</surname><given-names>A.Y.</given-names></name>
<name><surname>Seifert</surname><given-names>H.</given-names></name>
<name><surname>Paterson</surname><given-names>D.L.</given-names></name>
</person-group><article-title><italic toggle="yes">Acinetobacter baumannii</italic>: Emergence of a successful pathogen</article-title><source>Clin. Microbiol. Rev.</source><year>2008</year><volume>21</volume><fpage>538</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1128/CMR.00058-07</pub-id><pub-id pub-id-type="pmid">18625687</pub-id></element-citation></ref><ref id="B22-microorganisms-10-01052"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheikhalizadeh</surname><given-names>V.</given-names></name>
<name><surname>Hasani</surname><given-names>A.</given-names></name>
<name><surname>Rezaee</surname><given-names>M.A.</given-names></name>
<name><surname>Rahmati-Yamchi</surname><given-names>M.</given-names></name>
<name><surname>Hasani</surname><given-names>A.</given-names></name>
<name><surname>Ghotaslou</surname><given-names>R.</given-names></name>
<name><surname>Goli</surname><given-names>H.R.</given-names></name>
</person-group><article-title>Comprehensive study to investigate the role of various aminoglycoside resistance mechanisms in clinical isolates of <italic toggle="yes">Acinetobacter baumannii</italic></article-title><source>J. Infect. Chemother.</source><year>2017</year><volume>23</volume><fpage>74</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2016.09.012</pub-id><?supplied-pmid 27889248?><pub-id pub-id-type="pmid">27889248</pub-id></element-citation></ref><ref id="B23-microorganisms-10-01052"><label>23.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>GERMS-SA</collab>
</person-group><article-title>GERMS-SA Annual Report 2019</article-title><comment>Available online: <ext-link xlink:href="https://www.nicd.ac.za/wp-content/uploads/2019/11/GERMS-SAAR-2018-Final.pdf" ext-link-type="uri">https://www.nicd.ac.za/wp-content/uploads/2019/11/GERMS-SAAR-2018-Final.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-05-15">(accessed on 15 May 2022)</date-in-citation></element-citation></ref><ref id="B24-microorganisms-10-01052"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chapartegui-Gonz&#x000e1;lez</surname><given-names>I.</given-names></name>
<name><surname>L&#x000e1;zaro-D&#x000ed;ez</surname><given-names>M.</given-names></name>
<name><surname>Redondo-Salvo</surname><given-names>S.</given-names></name>
<name><surname>Navas</surname><given-names>J.</given-names></name>
<name><surname>Ramos-Vivas</surname><given-names>J.</given-names></name>
</person-group><article-title>Antimicrobial resistance determinants in genomes and plasmids from <italic toggle="yes">Acinetobacter baumannii</italic> clinical isolates</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>753</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10070753</pub-id><pub-id pub-id-type="pmid">34206348</pub-id></element-citation></ref><ref id="B25-microorganisms-10-01052"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jouybari</surname><given-names>M.A.</given-names></name>
<name><surname>Ahanjan</surname><given-names>M.</given-names></name>
<name><surname>Mirzaei</surname><given-names>B.</given-names></name>
<name><surname>Goli</surname><given-names>H.R.</given-names></name>
</person-group><article-title>Role of aminoglycoside-modifying enzymes and 16S rRNA methylase (ArmA) in resistance of <italic toggle="yes">Acinetobacter baumannii</italic> clinical isolates against aminoglycosides</article-title><source>Rev. Soc. Bras. Med. Trop.</source><year>2021</year><volume>29</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1590/0037-8682-0599-2020</pub-id><?supplied-pmid 33533819?><pub-id pub-id-type="pmid">33533819</pub-id></element-citation></ref><ref id="B26-microorganisms-10-01052"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>E.J.</given-names></name>
<name><surname>Courvalin</surname><given-names>P.</given-names></name>
<name><surname>Grillot-Courvalin</surname><given-names>C.</given-names></name>
</person-group><article-title>RND-type efflux pumps in multidrug-resistant clinical isolates of <italic toggle="yes">Acinetobacter baumannii:</italic> Major role for AdeABC overexpression and AdeRS mutations</article-title><source>Antimicrob. Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>2989</fpage><lpage>2995</lpage><pub-id pub-id-type="doi">10.1128/AAC.02556-12</pub-id><?supplied-pmid 23587960?><pub-id pub-id-type="pmid">23587960</pub-id></element-citation></ref><ref id="B27-microorganisms-10-01052"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beheshti</surname><given-names>M.</given-names></name>
<name><surname>Ardebili</surname><given-names>A.</given-names></name>
<name><surname>Beheshti</surname><given-names>F.</given-names></name>
<name><surname>Lari</surname><given-names>A.R.</given-names></name>
<name><surname>Siyadatpanah</surname><given-names>A.</given-names></name>
<name><surname>Pournajaf</surname><given-names>A.</given-names></name>
<name><surname>Gautam</surname><given-names>D.</given-names></name>
<name><surname>Dolma</surname><given-names>K.G.</given-names></name>
<name><surname>Nissapatorn</surname><given-names>V.</given-names></name>
</person-group><article-title>Tetracycline resistance mediated by <italic toggle="yes">tet</italic> efflux pumps in clinical isolates of <italic toggle="yes">Acinetobacter baumannii</italic></article-title><source>Rev. Inst. Med. Trop.</source><year>2020</year><volume>62</volume><elocation-id>e88</elocation-id><pub-id pub-id-type="doi">10.1590/s1678-9946202062088</pub-id></element-citation></ref><ref id="B28-microorganisms-10-01052"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foong</surname><given-names>W.E.</given-names></name>
<name><surname>Wilhelm</surname><given-names>J.</given-names></name>
<name><surname>Tam</surname><given-names>H.K.</given-names></name>
<name><surname>Pos</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Tigecycline efflux in <italic toggle="yes">Acinetobacter baumannii</italic> is mediated by TetA in synergy with RND-type efflux transporters</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>1135</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa015</pub-id><pub-id pub-id-type="pmid">32049277</pub-id></element-citation></ref><ref id="B29-microorganisms-10-01052"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Butler</surname><given-names>D.A.</given-names></name>
<name><surname>Biagi</surname><given-names>M.</given-names></name>
<name><surname>Tan</surname><given-names>X.</given-names></name>
<name><surname>Qasmieh</surname><given-names>S.</given-names></name>
<name><surname>Bulman</surname><given-names>Z.P.</given-names></name>
<name><surname>Wenzler</surname><given-names>E.</given-names></name>
</person-group><article-title>Multidrug resistant <italic toggle="yes">Acinetobacter baumannii:</italic> Resistance by any other name would still be hard to treat</article-title><source>Curr. Infect. Dis. Rep.</source><year>2019</year><volume>21</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1007/s11908-019-0706-5</pub-id><pub-id pub-id-type="pmid">31734740</pub-id></element-citation></ref><ref id="B30-microorganisms-10-01052"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kyriakidis</surname><given-names>I.</given-names></name>
<name><surname>Vasileiou</surname><given-names>E.</given-names></name>
<name><surname>Pana</surname><given-names>Z.D.</given-names></name>
<name><surname>Tragiannidis</surname><given-names>A.</given-names></name>
</person-group><article-title><italic toggle="yes">Acinetobacter baumannii</italic> antibiotic resistance mechanisms</article-title><source>Pathogens</source><year>2021</year><volume>10</volume><elocation-id>373</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10030373</pub-id><pub-id pub-id-type="pmid">33808905</pub-id></element-citation></ref><ref id="B31-microorganisms-10-01052"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Walsh</surname><given-names>T.R.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<name><surname>Lv</surname><given-names>Y.</given-names></name>
<name><surname>Ke</surname><given-names>Y.</given-names></name>
<name><surname>Ji</surname><given-names>Q.</given-names></name>
<name><surname>Wei</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<etal/>
</person-group><article-title>Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans</article-title><source>Nat. Microbiol.</source><year>2019</year><volume>4</volume><fpage>1450</fpage><lpage>1456</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0445-2</pub-id><pub-id pub-id-type="pmid">31133751</pub-id></element-citation></ref><ref id="B32-microorganisms-10-01052"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Lv</surname><given-names>Y.</given-names></name>
<name><surname>Cui</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Song</surname><given-names>H.</given-names></name>
<name><surname>Hao</surname><given-names>Y.</given-names></name>
<name><surname>Shen</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Novel plasmid-mediated <italic toggle="yes">tet</italic> (X5) gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinical <italic toggle="yes">Acinetobacter baumannii</italic> isolate</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>64</volume><elocation-id>e01326-19</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.01326-19</pub-id><pub-id pub-id-type="pmid">31611352</pub-id></element-citation></ref><ref id="B33-microorganisms-10-01052"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Deng</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>K.</given-names></name>
<name><surname>Gao</surname><given-names>L.</given-names></name>
</person-group><article-title>Treatment of severe ventriculitis caused by extensively drug-resistant <italic toggle="yes">Acinetobacter baumannii</italic> by intraventricular lavage and administration of colistin</article-title><source>Infect. Drug Resist.</source><year>2019</year><volume>12</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.2147/IDR.S186646</pub-id><?supplied-pmid 30718963?><pub-id pub-id-type="pmid">30718963</pub-id></element-citation></ref><ref id="B34-microorganisms-10-01052"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lima</surname><given-names>W.G.</given-names></name>
<name><surname>Alves</surname><given-names>M.C.</given-names></name>
<name><surname>Cruz</surname><given-names>W.S.</given-names></name>
<name><surname>Paiva</surname><given-names>M.C.</given-names></name>
</person-group><article-title>Chromosomally encoded and plasmid-mediated polymyxins resistance in <italic toggle="yes">Acinetobacter baumannii</italic>: A huge public health threat</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2018</year><volume>37</volume><fpage>1009</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1007/s10096-018-3223-9</pub-id><?supplied-pmid 29524060?><pub-id pub-id-type="pmid">29524060</pub-id></element-citation></ref><ref id="B35-microorganisms-10-01052"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rebelo</surname><given-names>A.R.</given-names></name>
<name><surname>Bortolaia</surname><given-names>V.</given-names></name>
<name><surname>Kjeldgaard</surname><given-names>J.S.</given-names></name>
<name><surname>Pedersen</surname><given-names>S.K.</given-names></name>
<name><surname>Leekitcharoenphon</surname><given-names>P.</given-names></name>
<name><surname>Hansen</surname><given-names>I.M.</given-names></name>
<name><surname>Guerra</surname><given-names>B.</given-names></name>
<name><surname>Malorny</surname><given-names>B.</given-names></name>
<name><surname>Borowiak</surname><given-names>M.</given-names></name>
<name><surname>Hammerl</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, <italic toggle="yes">mcr-1</italic>, <italic toggle="yes">mcr-2</italic>, <italic toggle="yes">mcr-3</italic>, <italic toggle="yes">mcr-4</italic> and <italic toggle="yes">mcr-5</italic> for surveillance purposes</article-title><source>Eurosurveillance</source><year>2018</year><volume>23</volume><elocation-id>17-00672</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2018.23.6.17-00672</pub-id><?supplied-pmid 29439754?><pub-id pub-id-type="pmid">29439754</pub-id></element-citation></ref><ref id="B36-microorganisms-10-01052"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hameed</surname><given-names>F.</given-names></name>
<name><surname>Khan</surname><given-names>M.A.</given-names></name>
<name><surname>Muhammad</surname><given-names>H.</given-names></name>
<name><surname>Sarwar</surname><given-names>T.</given-names></name>
<name><surname>Bilal</surname><given-names>H.</given-names></name>
<name><surname>Rehman</surname><given-names>T.U.</given-names></name>
</person-group><article-title>Plasmid-mediated <italic toggle="yes">mcr-1</italic> gene in <italic toggle="yes">Acinetobacter baumannii</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic>: First report from Pakistan</article-title><source>Rev. Soc. Bras. Med.</source><year>2019</year><volume>52</volume><fpage>e20190237</fpage><pub-id pub-id-type="doi">10.1590/0037-8682-0237-2019</pub-id></element-citation></ref><ref id="B37-microorganisms-10-01052"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>F.</given-names></name>
<name><surname>Shen</surname><given-names>C.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Zhong</surname><given-names>L.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Liao</surname><given-names>K.</given-names></name>
<name><surname>Xia</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>G.B.</given-names></name>
<etal/>
</person-group><article-title>Identification of a novel plasmid carrying <italic toggle="yes">mcr-4.3</italic> in an <italic toggle="yes">Acinetobacter baumannii</italic> strain in China</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><elocation-id>e00133-19</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.00133-19</pub-id><pub-id pub-id-type="pmid">30936095</pub-id></element-citation></ref><ref id="B38-microorganisms-10-01052"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martins-Sorenson</surname><given-names>N.</given-names></name>
<name><surname>Snesrud</surname><given-names>E.</given-names></name>
<name><surname>Xavier</surname><given-names>D.E.</given-names></name>
<name><surname>Cacci</surname><given-names>L.C.</given-names></name>
<name><surname>Iavarone</surname><given-names>A.T.</given-names></name>
<name><surname>McGann</surname><given-names>P.</given-names></name>
<name><surname>Riley</surname><given-names>L.W.</given-names></name>
<name><surname>Moreira</surname><given-names>B.M.</given-names></name>
</person-group><article-title>A novel plasmid-encoded <italic toggle="yes">mcr-4.3</italic> gene in a colistin-resistant <italic toggle="yes">Acinetobacter baumannii clinical</italic> strain</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>60</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz413</pub-id><pub-id pub-id-type="pmid">31578567</pub-id></element-citation></ref><ref id="B39-microorganisms-10-01052"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tipton</surname><given-names>K.A.</given-names></name>
<name><surname>Chin</surname><given-names>C.Y.</given-names></name>
<name><surname>Farokhyfar</surname><given-names>M.</given-names></name>
<name><surname>Weiss</surname><given-names>D.S.</given-names></name>
<name><surname>Rather</surname><given-names>P.N.</given-names></name>
</person-group><article-title>Role of capsule in resistance to disinfectants, host antimicrobials, and desiccation in <italic toggle="yes">Acinetobacter baumannii</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><elocation-id>e01188-18</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.01188-18</pub-id><pub-id pub-id-type="pmid">30297362</pub-id></element-citation></ref><ref id="B40-microorganisms-10-01052"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boll</surname><given-names>J.M.</given-names></name>
<name><surname>Tucker</surname><given-names>A.T.</given-names></name>
<name><surname>Klein</surname><given-names>D.R.</given-names></name>
<name><surname>Beltran</surname><given-names>A.M.</given-names></name>
<name><surname>Brodbelt</surname><given-names>J.S.</given-names></name>
<name><surname>Davies</surname><given-names>B.W.</given-names></name>
<name><surname>Trent</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Reinforcing lipid A acylation on the cell surface of <italic toggle="yes">Acinetobacter baumannii</italic> promotes cationic antimicrobial peptide resistance and desiccation survival</article-title><source>MBio</source><year>2015</year><volume>6</volume><elocation-id>e00478-15</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00478-15</pub-id><pub-id pub-id-type="pmid">25991684</pub-id></element-citation></ref><ref id="B41-microorganisms-10-01052"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rondelet</surname><given-names>A.</given-names></name>
<name><surname>Condemine</surname><given-names>G.</given-names></name>
</person-group><article-title>Type II secretion: The substrates that won&#x02019;t go away</article-title><source>Res. Microbiol.</source><year>2013</year><volume>164</volume><fpage>556</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1016/j.resmic.2013.03.005</pub-id><pub-id pub-id-type="pmid">23538405</pub-id></element-citation></ref><ref id="B42-microorganisms-10-01052"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>T.L.</given-names></name>
<name><surname>Waack</surname><given-names>U.</given-names></name>
<name><surname>Smith</surname><given-names>S.</given-names></name>
<name><surname>Mobley</surname><given-names>H.</given-names></name>
<name><surname>Sandkvist</surname><given-names>M.</given-names></name>
</person-group><article-title><italic toggle="yes">Acinetobacter baumannii</italic> is dependent on the type II secretion system and its substrate LipA for lipid utilization and in vivo fitness</article-title><source>J. Bacteriol.</source><year>2015</year><volume>198</volume><fpage>711</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1128/JB.00622-15</pub-id><pub-id pub-id-type="pmid">26668261</pub-id></element-citation></ref><ref id="B43-microorganisms-10-01052"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez</surname><given-names>A.</given-names></name>
<name><surname>Merino</surname><given-names>M.</given-names></name>
<name><surname>Rumbo-Feal</surname><given-names>S.</given-names></name>
<name><surname>&#x000c1;lvarez-Fraga</surname><given-names>L.</given-names></name>
<name><surname>Vallejo</surname><given-names>J.A.</given-names></name>
<name><surname>Beceiro</surname><given-names>A.</given-names></name>
<name><surname>Ohneck</surname><given-names>E.J.</given-names></name>
<name><surname>Mateos</surname><given-names>J.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Puente</surname><given-names>P.</given-names></name>
<name><surname>Actis</surname><given-names>L.A.</given-names></name>
<etal/>
</person-group><article-title>The FhaB/FhaC two-partner secretion system is involved in adhesion of <italic toggle="yes">Acinetobacter baumannii</italic> AbH12O-A2 strain</article-title><source>Virulence</source><year>2017</year><volume>8</volume><fpage>959</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1080/21505594.2016.1262313</pub-id><?supplied-pmid 27858524?><pub-id pub-id-type="pmid">27858524</pub-id></element-citation></ref><ref id="B44-microorganisms-10-01052"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roussin</surname><given-names>M.</given-names></name>
<name><surname>Rabarioelina</surname><given-names>S.</given-names></name>
<name><surname>Cluzeau</surname><given-names>L.</given-names></name>
<name><surname>Cayron</surname><given-names>J.</given-names></name>
<name><surname>Lesterlin</surname><given-names>C.</given-names></name>
<name><surname>Salcedo</surname><given-names>S.P.</given-names></name>
<name><surname>Bigot</surname><given-names>S.</given-names></name>
</person-group><article-title>Identification of a contact-dependent growth inhibition (CDI) system that reduces biofilm formation and host cell adhesion of <italic toggle="yes">Acinetobacter baumannii</italic> DSM30011 strain</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><elocation-id>2450</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.02450</pub-id><?supplied-pmid 31736897?><pub-id pub-id-type="pmid">31736897</pub-id></element-citation></ref><ref id="B45-microorganisms-10-01052"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>J.M.</given-names></name>
<name><surname>Deveson</surname><given-names>L.D.</given-names></name>
<name><surname>Harper</surname><given-names>M.</given-names></name>
</person-group><article-title>Systematic identification and analysis of <italic toggle="yes">Acinetobacter baumannii</italic> Type VI secretion system effector and immunity components</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><elocation-id>2440</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.02440</pub-id><?supplied-pmid 31736890?><pub-id pub-id-type="pmid">31736890</pub-id></element-citation></ref><ref id="B46-microorganisms-10-01052"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>J.</given-names></name>
<name><surname>Bergmann</surname><given-names>H.</given-names></name>
<name><surname>G&#x000f6;ttig</surname><given-names>S.</given-names></name>
<name><surname>Ebersberger</surname><given-names>I.</given-names></name>
<name><surname>Averhoff</surname><given-names>B.</given-names></name>
</person-group><article-title><italic toggle="yes">Acinetobacter baumannii</italic> virulence is mediated by the concerted action of three phospholipases D</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0138360</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0138360</pub-id><?supplied-pmid 26379240?><pub-id pub-id-type="pmid">26379240</pub-id></element-citation></ref><ref id="B47-microorganisms-10-01052"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Camarena</surname><given-names>L.</given-names></name>
<name><surname>Bruno</surname><given-names>V.</given-names></name>
<name><surname>Euskirchen</surname><given-names>G.</given-names></name>
<name><surname>Poggio</surname><given-names>S.</given-names></name>
<name><surname>Snyder</surname><given-names>M.</given-names></name>
</person-group><article-title>Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing</article-title><source>PLoS Pathog.</source><year>2010</year><volume>6</volume><elocation-id>e1000834</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000834</pub-id><pub-id pub-id-type="pmid">20368969</pub-id></element-citation></ref><ref id="B48-microorganisms-10-01052"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uppalapati</surname><given-names>S.R.</given-names></name>
<name><surname>Sett</surname><given-names>A.</given-names></name>
<name><surname>Pathania</surname><given-names>R.</given-names></name>
</person-group><article-title>The outer membrane proteins OmpA, CarO, and OprD of <italic toggle="yes">Acinetobacter baumannii</italic> confer a two-pronged defence in facilitating its success as a potent human pathogen</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>589234</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.589234</pub-id><pub-id pub-id-type="pmid">33123117</pub-id></element-citation></ref><ref id="B49-microorganisms-10-01052"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>Y.</given-names></name>
<name><surname>Unno</surname><given-names>Y.</given-names></name>
<name><surname>Kawakami</surname><given-names>S.</given-names></name>
<name><surname>Ubagai</surname><given-names>T.</given-names></name>
<name><surname>Ono</surname><given-names>Y.</given-names></name>
</person-group><article-title>Virulence characteristics of <italic toggle="yes">Acinetobacter baumannii</italic> clinical isolates vary with the expression levels of omps</article-title><source>J. Med. Microbiol.</source><year>2017</year><volume>66</volume><fpage>203</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.000394</pub-id><pub-id pub-id-type="pmid">27902395</pub-id></element-citation></ref><ref id="B50-microorganisms-10-01052"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colquhoun</surname><given-names>J.M.</given-names></name>
<name><surname>Rather</surname><given-names>P.N.</given-names></name>
</person-group><article-title>Insights into mechanisms of biofilm formation in <italic toggle="yes">Acinetobacter baumannii</italic> and implications for uropathogenesis</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>253</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.00253</pub-id><pub-id pub-id-type="pmid">32547965</pub-id></element-citation></ref><ref id="B51-microorganisms-10-01052"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khalil</surname><given-names>M.A.</given-names></name>
<name><surname>Ahmed</surname><given-names>F.A.</given-names></name>
<name><surname>Elkhateeb</surname><given-names>A.F.</given-names></name>
<name><surname>Mahmoud</surname><given-names>E.E.</given-names></name>
<name><surname>Ahmed</surname><given-names>M.I.</given-names></name>
<name><surname>Ahmed</surname><given-names>R.I.</given-names></name>
<name><surname>Hosni</surname><given-names>A.</given-names></name>
<name><surname>Alghamdi</surname><given-names>S.</given-names></name>
<name><surname>Kabrah</surname><given-names>A.</given-names></name>
<name><surname>Dablool</surname><given-names>A.S.</given-names></name>
<etal/>
</person-group><article-title>Virulence Characteristics of Biofilm-Forming <italic toggle="yes">Acinetobacter baumannii</italic> in Clinical Isolates Using a <italic toggle="yes">Galleria mellonella</italic> Model</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><elocation-id>2365</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms9112365</pub-id><pub-id pub-id-type="pmid">34835490</pub-id></element-citation></ref><ref id="B52-microorganisms-10-01052"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brossard</surname><given-names>K.A.</given-names></name>
<name><surname>Campagnari</surname><given-names>A.A.</given-names></name>
</person-group><article-title>The <italic toggle="yes">Acinetobacter baumannii</italic> biofilm-associated protein plays a role in adherence to human epithelial cells</article-title><source>Infect. Immun.</source><year>2012</year><volume>80</volume><fpage>228</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1128/IAI.05913-11</pub-id><pub-id pub-id-type="pmid">22083703</pub-id></element-citation></ref><ref id="B53-microorganisms-10-01052"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gregorio</surname><given-names>E.</given-names></name>
<name><surname>Roscetto</surname><given-names>E.</given-names></name>
<name><surname>Iula</surname><given-names>V.D.</given-names></name>
</person-group><article-title>Development of a real-time PCR assay for the rapid detection of <italic toggle="yes">Acinetobacter baumannii</italic> from whole blood samples</article-title><source>New Microbiol.</source><year>2015</year><volume>38</volume><fpage>251</fpage><lpage>257</lpage><?supplied-pmid 25938750?><pub-id pub-id-type="pmid">25938750</pub-id></element-citation></ref><ref id="B54-microorganisms-10-01052"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thummeepak</surname><given-names>R.</given-names></name>
<name><surname>Kongthai</surname><given-names>P.</given-names></name>
<name><surname>Leungtongkam</surname><given-names>U.</given-names></name>
<name><surname>Sitthisak</surname><given-names>S.</given-names></name>
</person-group><article-title>Distribution of virulence genes involved in biofilm formation in multi-drug resistant <italic toggle="yes">Acinetobacter baumannii</italic> clinical isolates</article-title><source>Int. Microbiol.</source><year>2016</year><volume>19</volume><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.2436/20.1501.01.270</pub-id><?supplied-pmid 27845499?><pub-id pub-id-type="pmid">27845499</pub-id></element-citation></ref><ref id="B55-microorganisms-10-01052"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Donadu</surname><given-names>M.G.</given-names></name>
<name><surname>Mazzarello</surname><given-names>V.</given-names></name>
<name><surname>Cappuccinelli</surname><given-names>P.</given-names></name>
<name><surname>Zanetti</surname><given-names>S.</given-names></name>
<name><surname>Madl&#x000e9;na</surname><given-names>M.</given-names></name>
<name><surname>Nagy</surname><given-names>&#x000c1;.L.</given-names></name>
<name><surname>St&#x000e1;jer</surname><given-names>A.</given-names></name>
<name><surname>Buri&#x000e1;n</surname><given-names>K.</given-names></name>
<name><surname>Gajd&#x000e1;cs</surname><given-names>M.</given-names></name>
</person-group><article-title>Relationship between the Biofilm-Forming Capacity and Antimicrobial Resistance in Clinical <italic toggle="yes">Acinetobacter baumannii</italic> Isolates: Results from a Laboratory-Based In Vitro Study</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><elocation-id>2384</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms9112384</pub-id><?supplied-pmid 34835509?><pub-id pub-id-type="pmid">34835509</pub-id></element-citation></ref><ref id="B56-microorganisms-10-01052"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roy</surname><given-names>S.</given-names></name>
<name><surname>Chowdhury</surname><given-names>G.</given-names></name>
<name><surname>Mukhopadhyay</surname><given-names>A.K.</given-names></name>
<name><surname>Dutta</surname><given-names>S.</given-names></name>
<name><surname>Basu</surname><given-names>S.</given-names></name>
</person-group><article-title>Convergence of Biofilm Formation and Antibiotic Resistance in <italic toggle="yes">Acinetobacter baumannii</italic> Infection</article-title><source>Front. Med.</source><year>2022</year><volume>9</volume><elocation-id>793615</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2022.793615</pub-id><?supplied-pmid 35402433?><pub-id pub-id-type="pmid">35402433</pub-id></element-citation></ref><ref id="B57-microorganisms-10-01052"><label>57.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics 2017</article-title><comment>Available online: <ext-link xlink:href="http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf" ext-link-type="uri">http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-01-01">(accessed on 1 January 2021)</date-in-citation></element-citation></ref><ref id="B58-microorganisms-10-01052"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ankaiah</surname><given-names>D.</given-names></name>
<name><surname>Palanichamy</surname><given-names>E.</given-names></name>
<name><surname>Antonyraj</surname><given-names>C.B.</given-names></name>
<name><surname>Ayyanna</surname><given-names>R.</given-names></name>
<name><surname>Perumal</surname><given-names>V.</given-names></name>
<name><surname>Ahamed</surname><given-names>S.I.B.</given-names></name>
<name><surname>Arul</surname><given-names>V.</given-names></name>
</person-group><article-title>Cloning, overexpression, purification of bacteriocin enterocin-B and structural analysis, interaction determination of enterocin-A, B against pathogenic bacteria and human cancer cells</article-title><source>Int. J. Biol. Macromol.</source><year>2018</year><volume>116</volume><fpage>502</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.05.002</pub-id><pub-id pub-id-type="pmid">29729340</pub-id></element-citation></ref><ref id="B59-microorganisms-10-01052"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chi</surname><given-names>H.</given-names></name>
<name><surname>Holo</surname><given-names>H.</given-names></name>
</person-group><article-title>Synergistic antimicrobial activity between the broad spectrum bacteriocin garvicin KS and nisin, farnesol and polymyxin B against gram-positive and gram-negative bacteria</article-title><source>Curr. Microbiol.</source><year>2018</year><volume>75</volume><fpage>272</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1007/s00284-017-1375-y</pub-id><pub-id pub-id-type="pmid">29058043</pub-id></element-citation></ref><ref id="B60-microorganisms-10-01052"><label>60.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Henkel</surname><given-names>M.</given-names></name>
<name><surname>Hausmann</surname><given-names>R.</given-names></name>
</person-group><article-title>Diversity and classification of microbial surfactants</article-title><source>Biobased Surfactants</source><edition>2nd ed.</edition><person-group person-group-type="editor">
<name><surname>Hayes</surname><given-names>D.G.</given-names></name>
<name><surname>Solaiman</surname><given-names>D.K.Y.</given-names></name>
<name><surname>Ashby</surname><given-names>R.D.</given-names></name>
</person-group><publisher-name>AOCS Press</publisher-name><publisher-loc>Urbana, OH, USA</publisher-loc><year>2019</year><fpage>41</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-812705-6.00002-2</pub-id></element-citation></ref><ref id="B61-microorganisms-10-01052"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Havenga</surname><given-names>B.</given-names></name>
<name><surname>Ndlovu</surname><given-names>T.</given-names></name>
<name><surname>Clements</surname><given-names>T.</given-names></name>
<name><surname>Reyneke</surname><given-names>B.</given-names></name>
<name><surname>Waso</surname><given-names>M.</given-names></name>
<name><surname>Khan</surname><given-names>W.</given-names></name>
</person-group><article-title>Exploring the antimicrobial resistance profiles of WHO critical priority list bacterial strains</article-title><source>BMC Microbiol.</source><year>2019</year><volume>19</volume><elocation-id>303</elocation-id><pub-id pub-id-type="doi">10.1186/s12866-019-1687-0</pub-id><pub-id pub-id-type="pmid">31870288</pub-id></element-citation></ref><ref id="B62-microorganisms-10-01052"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meena</surname><given-names>K.R.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Kanwar</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Antitumoral and antimicrobial activity of surfactin extracted from <italic toggle="yes">Bacillus subtilis</italic> KLP2015</article-title><source>Int. J. Pept. Res.</source><year>2020</year><volume>26</volume><fpage>423</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1007/s10989-019-09848-w</pub-id></element-citation></ref><ref id="B63-microorganisms-10-01052"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kikuchi</surname><given-names>T.</given-names></name>
<name><surname>Hasumi</surname><given-names>K.</given-names></name>
</person-group><article-title>Enhancement of plasminogen activation by surfactin C: Augmentation of fibrinolysis in vitro and in vivo</article-title><source>Biochim. Biophys. Acta Protein Struct. Mol. Enzymol.</source><year>2002</year><volume>1596</volume><fpage>234</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/S0167-4838(02)00221-2</pub-id></element-citation></ref><ref id="B64-microorganisms-10-01052"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hwang</surname><given-names>Y.H.</given-names></name>
<name><surname>Park</surname><given-names>B.K.</given-names></name>
<name><surname>Lim</surname><given-names>J.H.</given-names></name>
<name><surname>Kim</surname><given-names>M.S.</given-names></name>
<name><surname>Park</surname><given-names>S.C.</given-names></name>
<name><surname>Hwang</surname><given-names>M.H.</given-names></name>
<name><surname>Yun</surname><given-names>H.I.</given-names></name>
</person-group><article-title>Lipopolysaccharide-binding and neutralizing activities of surfactin C in experimental models of septic shock</article-title><source>Eur. J. Pharmacol.</source><year>2007</year><volume>556</volume><fpage>166</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2006.10.031</pub-id><pub-id pub-id-type="pmid">17126323</pub-id></element-citation></ref><ref id="B65-microorganisms-10-01052"><label>65.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Water Research Commission</collab>
</person-group><source>Bioprospecting for Biosurfactant Producing Bacteria, WRC Report Project No. K5/2728//3</source><publisher-name>Water Research Commission</publisher-name><publisher-loc>Pretoria, South Africa</publisher-loc><year>2019</year><volume>Volume 1</volume></element-citation></ref><ref id="B66-microorganisms-10-01052"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shanks</surname><given-names>R.M.</given-names></name>
<name><surname>Stella</surname><given-names>N.A.</given-names></name>
<name><surname>Lahr</surname><given-names>R.M.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Veverka</surname><given-names>T.I.</given-names></name>
<name><surname>Kowalski</surname><given-names>R.P.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
</person-group><article-title>Serratamolide is a hemolytic factor produced by <italic toggle="yes">Serratia marcescens</italic></article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e36398</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0036398</pub-id><?supplied-pmid 22615766?><pub-id pub-id-type="pmid">22615766</pub-id></element-citation></ref><ref id="B67-microorganisms-10-01052"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aleksic</surname><given-names>I.</given-names></name>
<name><surname>Petkovic</surname><given-names>M.</given-names></name>
<name><surname>Jovanovic</surname><given-names>M.</given-names></name>
<name><surname>Milivojevic</surname><given-names>D.</given-names></name>
<name><surname>Vasiljevic</surname><given-names>B.</given-names></name>
<name><surname>Nikodinovic-Runic</surname><given-names>J.</given-names></name>
<name><surname>Senerovic</surname><given-names>L.</given-names></name>
</person-group><article-title>Anti-biofilm properties of bacterial di-rhamnolipids and their semi-synthetic amide derivatives</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><elocation-id>2454</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.02454</pub-id><?supplied-pmid 29276509?><pub-id pub-id-type="pmid">29276509</pub-id></element-citation></ref><ref id="B68-microorganisms-10-01052"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thanomsub</surname><given-names>B.</given-names></name>
<name><surname>Pumeechockchai</surname><given-names>W.</given-names></name>
<name><surname>Limtrakul</surname><given-names>A.</given-names></name>
<name><surname>Arunrattiyakorn</surname><given-names>P.</given-names></name>
<name><surname>Petchleelaha</surname><given-names>W.</given-names></name>
<name><surname>Nitoda</surname><given-names>T.</given-names></name>
<name><surname>Kanzaki</surname><given-names>H.</given-names></name>
</person-group><article-title>Chemical structures and biological activities of rhamnolipids produced by <italic toggle="yes">Pseudomonas aeruginosa</italic> B189 isolated from milk factory waste</article-title><source>Bioresour. Technol.</source><year>2006</year><volume>97</volume><fpage>2457</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1016/j.biortech.2005.10.029</pub-id><?supplied-pmid 16697639?><pub-id pub-id-type="pmid">16697639</pub-id></element-citation></ref><ref id="B69-microorganisms-10-01052"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tawfeeq</surname><given-names>M.H.</given-names></name>
<name><surname>Yesser</surname><given-names>B.S.</given-names></name>
</person-group><article-title>Study of inhibitory activity for rhamnolipid produced by <italic toggle="yes">Pseudomonas aeruginosa</italic> against some types of pathogenic bacteria in vivo</article-title><source>Al-Qadisiyah J. Pure Sci.</source><year>2018</year><volume>23</volume><fpage>34</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.29350/jops.2018.23.1.714</pub-id></element-citation></ref><ref id="B70-microorganisms-10-01052"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balleza</surname><given-names>D.</given-names></name>
<name><surname>Alessandrini</surname><given-names>A.</given-names></name>
<name><surname>Beltr&#x000e1;n Garc&#x000ed;a</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Role of lipid composition, physicochemical interactions, and membrane mechanics in the molecular actions of microbial cyclic lipopeptides</article-title><source>J. Membr. Biol.</source><year>2019</year><volume>252</volume><fpage>131</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1007/s00232-019-00067-4</pub-id><?supplied-pmid 31098678?><pub-id pub-id-type="pmid">31098678</pub-id></element-citation></ref><ref id="B71-microorganisms-10-01052"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samadi</surname><given-names>N.</given-names></name>
<name><surname>Abadian</surname><given-names>N.</given-names></name>
<name><surname>Ahmadkhaniha</surname><given-names>R.</given-names></name>
<name><surname>Amini</surname><given-names>F.</given-names></name>
<name><surname>Dalili</surname><given-names>D.</given-names></name>
<name><surname>Rastkari</surname><given-names>N.</given-names></name>
<name><surname>Safaripour</surname><given-names>E.</given-names></name>
<name><surname>Mohseni</surname><given-names>F.A.</given-names></name>
</person-group><article-title>Structural characterization and surface activities of biogenic rhamnolipid surfactants from <italic toggle="yes">Pseudomonas aeruginosa</italic> isolate MN1 and synergistic effects against methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Folia Microbiol.</source><year>2012</year><volume>57</volume><fpage>501</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1007/s12223-012-0164-z</pub-id><?supplied-pmid 22644668?><pub-id pub-id-type="pmid">22644668</pub-id></element-citation></ref><ref id="B72-microorganisms-10-01052"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sudarmono</surname><given-names>P.</given-names></name>
<name><surname>Wibisana</surname><given-names>A.</given-names></name>
<name><surname>Listriyani</surname><given-names>L.W.</given-names></name>
<name><surname>Sungkar</surname><given-names>S.</given-names></name>
</person-group><article-title>Characterization and synergistic antimicrobial evaluation of lipopeptides from <italic toggle="yes">Bacillus amyloliquefaciens</italic> isolated from oil-contaminated soil</article-title><source>Int. J. Microbiol.</source><year>2019</year><volume>2019</volume><elocation-id>3704198</elocation-id><pub-id pub-id-type="doi">10.1155/2019/3704198</pub-id><?supplied-pmid 30956662?><pub-id pub-id-type="pmid">30956662</pub-id></element-citation></ref><ref id="B73-microorganisms-10-01052"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Henkel</surname><given-names>M.</given-names></name>
<name><surname>Geissler</surname><given-names>M.</given-names></name>
<name><surname>Weggenmann</surname><given-names>F.</given-names></name>
<name><surname>Hausmann</surname><given-names>R.</given-names></name>
</person-group><article-title>Production of microbial biosurfactants: Status quo of rhamnolipid and surfactin towards large-scale production</article-title><source>Biotechnol. J.</source><year>2017</year><volume>12</volume><elocation-id>1600561</elocation-id><pub-id pub-id-type="doi">10.1002/biot.201600561</pub-id></element-citation></ref><ref id="B74-microorganisms-10-01052"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banat</surname><given-names>I.M.</given-names></name>
<name><surname>Satpute</surname><given-names>S.K.</given-names></name>
<name><surname>Cameotra</surname><given-names>S.S.</given-names></name>
<name><surname>Patil</surname><given-names>R.</given-names></name>
<name><surname>Nyayanit</surname><given-names>N.V.</given-names></name>
</person-group><article-title>Cost effective technologies and renewable substrates for biosurfactants&#x02019; production</article-title><source>Front. Microbiol.</source><year>2014</year><volume>5</volume><elocation-id>697</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2014.00697</pub-id><pub-id pub-id-type="pmid">25566213</pub-id></element-citation></ref><ref id="B75-microorganisms-10-01052"><label>75.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Montgomery</surname><given-names>D.C.</given-names></name>
</person-group><source>Design and Analysis of Experiments: Response Surface Method and Designs</source><person-group person-group-type="editor">
<name><surname>Hinkelmann</surname><given-names>K.</given-names></name>
</person-group><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2005</year></element-citation></ref><ref id="B76-microorganisms-10-01052"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wibisana</surname><given-names>A.</given-names></name>
<name><surname>Sumaryono</surname><given-names>W.</given-names></name>
<name><surname>Sudiro</surname><given-names>M.</given-names></name>
<name><surname>Sudarmono</surname><given-names>P.P.</given-names></name>
</person-group><article-title>Optimization of surfactin production by <italic toggle="yes">Bacillus amyloliquefaciens</italic> MD4-12 using response surface methodology</article-title><source>Microbiol. Indones.</source><year>2015</year><volume>9</volume><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.5454/mi.9.3.4</pub-id></element-citation></ref><ref id="B77-microorganisms-10-01052"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiao</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Shen</surname><given-names>Z.</given-names></name>
</person-group><article-title>In situ enhancement of surfactin biosynthesis in <italic toggle="yes">Bacillus subtilis</italic> using novel artificial inducible promoters</article-title><source>Biotechnol. Bioeng.</source><year>2017</year><volume>114</volume><fpage>832</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1002/bit.26197</pub-id><?supplied-pmid 27723092?><pub-id pub-id-type="pmid">27723092</pub-id></element-citation></ref><ref id="B78-microorganisms-10-01052"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mulligan</surname><given-names>C.N.</given-names></name>
<name><surname>Chow</surname><given-names>T.Y.K.</given-names></name>
<name><surname>Gibbs</surname><given-names>B.F.</given-names></name>
</person-group><article-title>Enhanced biosurfactant production by a mutant <italic toggle="yes">Bacillus subtilis</italic> strain</article-title><source>Appl. Microbiol. Biotechnol.</source><year>1989</year><volume>31</volume><fpage>486</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1007/BF00270781</pub-id></element-citation></ref><ref id="B79-microorganisms-10-01052"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>S.C.</given-names></name>
<name><surname>Lin</surname><given-names>K.G.</given-names></name>
<name><surname>Lo</surname><given-names>C.C.</given-names></name>
<name><surname>Lin</surname><given-names>Y.M.</given-names></name>
</person-group><article-title>Enhanced biosurfactant production by a <italic toggle="yes">Bacillus licheniformis</italic> mutant</article-title><source>Enzyme Microb. Technol.</source><year>1998</year><volume>23</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/S0141-0229(98)00049-0</pub-id></element-citation></ref><ref id="B80-microorganisms-10-01052"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jimoh</surname><given-names>A.A.</given-names></name>
<name><surname>Senbadejo</surname><given-names>T.Y.</given-names></name>
<name><surname>Adeleke</surname><given-names>R.</given-names></name>
<name><surname>Lin</surname><given-names>J.</given-names></name>
</person-group><article-title>Development and genetic engineering of hyper-producing microbial strains for improved synthesis of biosurfactants</article-title><source>Mol. Biotechnol.</source><year>2021</year><volume>63</volume><fpage>267</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1007/s12033-021-00302-1</pub-id><pub-id pub-id-type="pmid">33523418</pub-id></element-citation></ref><ref id="B81-microorganisms-10-01052"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>K.O.</given-names></name>
<name><surname>Ramzi</surname><given-names>A.B.</given-names></name>
<name><surname>Choe</surname><given-names>S.H.</given-names></name>
<name><surname>Kim</surname><given-names>S.W.</given-names></name>
<name><surname>Han</surname><given-names>S.O.</given-names></name>
</person-group><article-title>Improvement of surfactin production in <italic toggle="yes">Bacillus subtilis</italic> using synthetic wastewater by overexpression of specific extracellular signaling peptides, comX and phrC</article-title><source>Biotechnol. Bioeng.</source><year>2012</year><volume>109</volume><fpage>2349</fpage><lpage>2356</lpage><pub-id pub-id-type="doi">10.1002/bit.24524</pub-id><pub-id pub-id-type="pmid">22511326</pub-id></element-citation></ref><ref id="B82-microorganisms-10-01052"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marine</surname><given-names>E.</given-names></name>
<name><surname>Milner</surname><given-names>D.S.</given-names></name>
<name><surname>Lambert</surname><given-names>C.</given-names></name>
<name><surname>Sockett</surname><given-names>R.E.</given-names></name>
<name><surname>Pos</surname><given-names>K.M.</given-names></name>
</person-group><article-title>A novel method to determine antibiotic sensitivity in <italic toggle="yes">Bdellovibrio bacteriovorus</italic> reveals a DHFR-dependent natural trimethoprim resistance</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>5315</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-62014-x</pub-id><pub-id pub-id-type="pmid">32210253</pub-id></element-citation></ref><ref id="B83-microorganisms-10-01052"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bratanis</surname><given-names>E.</given-names></name>
<name><surname>Andersson</surname><given-names>T.</given-names></name>
<name><surname>Lood</surname><given-names>R.</given-names></name>
<name><surname>Bukowska-Faniband</surname><given-names>E.</given-names></name>
</person-group><article-title>Biotechnological potential of <italic toggle="yes">Bdellovibrio</italic> and like organisms and their secreted enzymes</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>662</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.00662</pub-id><pub-id pub-id-type="pmid">32351487</pub-id></element-citation></ref><ref id="B84-microorganisms-10-01052"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shemesh</surname><given-names>Y.</given-names></name>
<name><surname>Jurkevitch</surname><given-names>E.</given-names></name>
</person-group><article-title>Plastic phenotypic resistance to predation by <italic toggle="yes">Bdellovibrio</italic> and like organisms in bacterial prey</article-title><source>Environ. Microbiol.</source><year>2004</year><volume>6</volume><fpage>12</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1046/j.1462-2920.2003.00530.x</pub-id><pub-id pub-id-type="pmid">14686937</pub-id></element-citation></ref><ref id="B85-microorganisms-10-01052"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kadouri</surname><given-names>D.E.</given-names></name>
<name><surname>To</surname><given-names>K.</given-names></name>
<name><surname>Shanks</surname><given-names>R.M.</given-names></name>
<name><surname>Doi</surname><given-names>Y.</given-names></name>
</person-group><article-title>Predatory bacteria: A potential ally against multidrug-resistant Gram-negative pathogens</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e63397</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0063397</pub-id><pub-id pub-id-type="pmid">23650563</pub-id></element-citation></ref><ref id="B86-microorganisms-10-01052"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dharani</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>D.H.</given-names></name>
<name><surname>Shanks</surname><given-names>R.M.</given-names></name>
<name><surname>Doi</surname><given-names>Y.</given-names></name>
<name><surname>Kadouri</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Susceptibility of colistin-resistant pathogens to predatory bacteria</article-title><source>Res. Microbiol.</source><year>2018</year><volume>169</volume><fpage>52</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.resmic.2017.09.001</pub-id><pub-id pub-id-type="pmid">28919044</pub-id></element-citation></ref><ref id="B87-microorganisms-10-01052"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shatzkes</surname><given-names>K.</given-names></name>
<name><surname>Singleton</surname><given-names>E.</given-names></name>
<name><surname>Tang</surname><given-names>C.</given-names></name>
<name><surname>Zuena</surname><given-names>M.</given-names></name>
<name><surname>Shukla</surname><given-names>S.</given-names></name>
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Dharani</surname><given-names>S.</given-names></name>
<name><surname>Onyile</surname><given-names>O.</given-names></name>
<name><surname>Rinaggio</surname><given-names>J.</given-names></name>
<name><surname>Connell</surname><given-names>N.D.</given-names></name>
<etal/>
</person-group><article-title>Predatory bacteria attenuate <italic toggle="yes">Klebsiella pneumoniae</italic> burden in rat lungs</article-title><source>MBio</source><year>2016</year><volume>7</volume><elocation-id>e01847-16</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.01847-16</pub-id><pub-id pub-id-type="pmid">27834203</pub-id></element-citation></ref><ref id="B88-microorganisms-10-01052"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Findlay</surname><given-names>J.S.</given-names></name>
<name><surname>Flick-Smith</surname><given-names>H.C.</given-names></name>
<name><surname>Keyser</surname><given-names>E.</given-names></name>
<name><surname>Cooper</surname><given-names>I.A.</given-names></name>
<name><surname>Williamson</surname><given-names>E.D.</given-names></name>
<name><surname>Oyston</surname><given-names>P.C.</given-names></name>
</person-group><article-title>Predatory bacteria can protect SKH-1 mice from a lethal plague challenge</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>7225</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-43467-1</pub-id><?supplied-pmid 31076594?><pub-id pub-id-type="pmid">31076594</pub-id></element-citation></ref><ref id="B89-microorganisms-10-01052"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shatzkes</surname><given-names>K.</given-names></name>
<name><surname>Singleton</surname><given-names>E.</given-names></name>
<name><surname>Tang</surname><given-names>C.</given-names></name>
<name><surname>Zuena</surname><given-names>M.</given-names></name>
<name><surname>Shukla</surname><given-names>S.</given-names></name>
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Dharani</surname><given-names>S.</given-names></name>
<name><surname>Rinaggio</surname><given-names>J.</given-names></name>
<name><surname>Kadouri</surname><given-names>D.E.</given-names></name>
<name><surname>Connell</surname><given-names>N.D.</given-names></name>
</person-group><article-title>Examining the efficacy of intravenous administration of predatory bacteria in rats</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>1864</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-02041-3</pub-id><?supplied-pmid 28500337?><pub-id pub-id-type="pmid">28500337</pub-id></element-citation></ref><ref id="B90-microorganisms-10-01052"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Im</surname><given-names>H.</given-names></name>
<name><surname>Choi</surname><given-names>S.Y.</given-names></name>
<name><surname>Son</surname><given-names>S.</given-names></name>
<name><surname>Mitchell</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Combined application of bacterial predation and violacein to kill polymicrobial pathogenic communities</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>14415</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-14567-7</pub-id><?supplied-pmid 29089523?><pub-id pub-id-type="pmid">29089523</pub-id></element-citation></ref><ref id="B91-microorganisms-10-01052"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Im</surname><given-names>H.</given-names></name>
<name><surname>Son</surname><given-names>S.</given-names></name>
<name><surname>Mitchell</surname><given-names>R.J.</given-names></name>
<name><surname>Ghim</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Serum albumin and osmolality inhibit <italic toggle="yes">Bdellovibrio bacteriovorus</italic> predation in human serum</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>5896</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-06272-2</pub-id><pub-id pub-id-type="pmid">28725056</pub-id></element-citation></ref><ref id="B92-microorganisms-10-01052"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>An</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
</person-group><article-title>Encapsulated <italic toggle="yes">Bdellovibrio</italic> powder as a potential bio-disinfectant against whiteleg shrimp-pathogenic Vibrios</article-title><source>Microorganisms</source><year>2019</year><volume>7</volume><elocation-id>244</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms7080244</pub-id></element-citation></ref><ref id="B93-microorganisms-10-01052"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monnappa</surname><given-names>A.K.</given-names></name>
<name><surname>Dwidar</surname><given-names>M.</given-names></name>
<name><surname>Seo</surname><given-names>J.K.</given-names></name>
<name><surname>Hur</surname><given-names>J.H.</given-names></name>
<name><surname>Mitchell</surname><given-names>R.J.</given-names></name>
</person-group><article-title><italic toggle="yes">Bdellovibrio bacteriovorus</italic> inhibits <italic toggle="yes">Staphylococcus aureus</italic> biofilm formation and invasion into human epithelial cells</article-title><source>Sci. Rep.</source><year>2014</year><volume>4</volume><elocation-id>3811</elocation-id><pub-id pub-id-type="doi">10.1038/srep03811</pub-id><pub-id pub-id-type="pmid">24448451</pub-id></element-citation></ref><ref id="B94-microorganisms-10-01052"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>C.H.</given-names></name>
<name><surname>Jin</surname><given-names>E.S.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Hwang</surname><given-names>E.T.</given-names></name>
</person-group><article-title>Immobilization and stabilization of enzyme in biomineralized calcium carbonate microspheres</article-title><source>Front. Bioeng. Biotechnol.</source><year>2020</year><volume>8</volume><fpage>1191</fpage><pub-id pub-id-type="doi">10.3389/fbioe.2020.553591</pub-id></element-citation></ref><ref id="B95-microorganisms-10-01052"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clokie</surname><given-names>M.R.</given-names></name>
<name><surname>Millard</surname><given-names>A.D.</given-names></name>
<name><surname>Letarov</surname><given-names>A.V.</given-names></name>
<name><surname>Heaphy</surname><given-names>S.</given-names></name>
</person-group><article-title>Phages in nature</article-title><source>Bacteriophage</source><year>2011</year><volume>1</volume><fpage>31</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.4161/bact.1.1.14942</pub-id><pub-id pub-id-type="pmid">21687533</pub-id></element-citation></ref><ref id="B96-microorganisms-10-01052"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brives</surname><given-names>C.</given-names></name>
<name><surname>Pourraz</surname><given-names>J.</given-names></name>
</person-group><article-title>Phage therapy as a potential solution in the fight against AMR: Obstacles and possible futures</article-title><source>Palgrave Commun.</source><year>2020</year><volume>6</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.1057/s41599-020-0478-4</pub-id></element-citation></ref><ref id="B97-microorganisms-10-01052"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hyman</surname><given-names>P.</given-names></name>
<name><surname>Abedon</surname><given-names>S.T.</given-names></name>
</person-group><article-title>Bacteriophage host range and bacterial resistance</article-title><source>Adv. Appl. Microbiol.</source><year>2010</year><volume>70</volume><fpage>217</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/S0065-2164(10)70007-1</pub-id><?supplied-pmid 20359459?><pub-id pub-id-type="pmid">20359459</pub-id></element-citation></ref><ref id="B98-microorganisms-10-01052"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Egido</surname><given-names>J.E.</given-names></name>
<name><surname>Costa</surname><given-names>A.R.</given-names></name>
<name><surname>Aparicio-Maldonado</surname><given-names>C.</given-names></name>
<name><surname>Haas</surname><given-names>P.J.</given-names></name>
<name><surname>Brouns</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Mechanisms and clinical importance of bacteriophage resistance</article-title><source>FEMS Microbiol. Rev.</source><year>2022</year><volume>6</volume><elocation-id>fuab048</elocation-id><pub-id pub-id-type="doi">10.1093/femsre/fuab048</pub-id><?supplied-pmid 34558600?><pub-id pub-id-type="pmid">34558600</pub-id></element-citation></ref><ref id="B99-microorganisms-10-01052"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wintachai</surname><given-names>P.</given-names></name>
<name><surname>Naknaen</surname><given-names>A.</given-names></name>
<name><surname>Pomwised</surname><given-names>R.</given-names></name>
<name><surname>Voravuthikunchai</surname><given-names>S.P.</given-names></name>
<name><surname>Smith</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Isolation and characterization of <italic toggle="yes">Siphoviridae</italic> phage infecting extensively drug-resistant <italic toggle="yes">Acinetobacter baumannii</italic> and evaluation of therapeutic efficacy in vitro and in vivo</article-title><source>J. Med. Microbiol.</source><year>2019</year><volume>68</volume><fpage>1096</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.001002</pub-id><?supplied-pmid 31169490?><pub-id pub-id-type="pmid">31169490</pub-id></element-citation></ref><ref id="B100-microorganisms-10-01052"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asif</surname><given-names>M.</given-names></name>
<name><surname>Alvi</surname><given-names>I.A.</given-names></name>
<name><surname>Tabassum</surname><given-names>R.</given-names></name>
<name><surname>Rehman</surname><given-names>S.U.</given-names></name>
</person-group><article-title>TAC1, an unclassified bacteriophage of the family <italic toggle="yes">Myoviridae</italic> infecting <italic toggle="yes">Acinetobacter baumannii</italic> with a large burst size and a short latent period</article-title><source>Arch. Virol.</source><year>2020</year><volume>165</volume><fpage>419</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1007/s00705-019-04483-8</pub-id><?supplied-pmid 31823011?><pub-id pub-id-type="pmid">31823011</pub-id></element-citation></ref><ref id="B101-microorganisms-10-01052"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>L.</given-names></name>
<name><surname>Tan</surname><given-names>J.</given-names></name>
<name><surname>Hao</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Yan</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Tuo</surname><given-names>L.</given-names></name>
<name><surname>Wei</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>G.</given-names></name>
</person-group><article-title>Isolation and characterization of a novel myophage Abp9 against pandrug resistant <italic toggle="yes">Acinetobacter baumannii</italic></article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><fpage>2138</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.506068</pub-id></element-citation></ref><ref id="B102-microorganisms-10-01052"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hua</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>T.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Dong</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>M.</given-names></name>
<name><surname>Guo</surname><given-names>X.</given-names></name>
<name><surname>Hu</surname><given-names>F.</given-names></name>
<name><surname>He</surname><given-names>P.</given-names></name>
</person-group><article-title>Phage therapy as a promising new treatment for lung infection caused by carbapenem-resistant <italic toggle="yes">Acinetobacter baumannii</italic> in mice</article-title><source>Front. Microbiol.</source><year>2018</year><volume>8</volume><elocation-id>2659</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.02659</pub-id><pub-id pub-id-type="pmid">29375524</pub-id></element-citation></ref><ref id="B103-microorganisms-10-01052"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeon</surname><given-names>J.</given-names></name>
<name><surname>Ryu</surname><given-names>C.M.</given-names></name>
<name><surname>Lee</surname><given-names>J.Y.</given-names></name>
<name><surname>Park</surname><given-names>J.H.</given-names></name>
<name><surname>Yong</surname><given-names>D.</given-names></name>
<name><surname>Lee</surname><given-names>K.</given-names></name>
</person-group><article-title>In vivo application of bacteriophage as a potential therapeutic agent to control OXA-66-like carbapenemase-producing <italic toggle="yes">Acinetobacter baumannii</italic> strains belonging to sequence type 357</article-title><source>Appl. Environ. Microbiol.</source><year>2016</year><volume>82</volume><fpage>4200</fpage><lpage>4208</lpage><pub-id pub-id-type="doi">10.1128/AEM.00526-16</pub-id><pub-id pub-id-type="pmid">27208124</pub-id></element-citation></ref><ref id="B104-microorganisms-10-01052"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
</person-group><article-title>Clinical experience of personalized phage therapy against carbapenem-resistant <italic toggle="yes">Acinetobacter baumannii</italic> lung infection in a patient with chronic obstructive pulmonary disease</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2021</year><volume>11</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2021.631585</pub-id></element-citation></ref><ref id="B105-microorganisms-10-01052"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>N.</given-names></name>
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Guo</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Qu</surname><given-names>H.</given-names></name>
<name><surname>Lu</surname><given-names>H.</given-names></name>
<name><surname>Jin</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Pre-optimized phage therapy on secondary <italic toggle="yes">Acinetobacter baumannii</italic> infection in four critical COVID-19 patients</article-title><source>Emerg. Microbes Infect.</source><year>2021</year><volume>10</volume><fpage>612</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1080/22221751.2021.1902754</pub-id><pub-id pub-id-type="pmid">33703996</pub-id></element-citation></ref><ref id="B106-microorganisms-10-01052"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Altamirano</surname><given-names>F.G.</given-names></name>
<name><surname>Forsyth</surname><given-names>J.H.</given-names></name>
<name><surname>Patwa</surname><given-names>R.</given-names></name>
<name><surname>Kostoulias</surname><given-names>X.</given-names></name>
<name><surname>Trim</surname><given-names>M.</given-names></name>
<name><surname>Subedi</surname><given-names>D.</given-names></name>
<name><surname>Archer</surname><given-names>S.</given-names></name>
<name><surname>Morris</surname><given-names>F.C.</given-names></name>
<name><surname>Oliveira</surname><given-names>C.</given-names></name>
<name><surname>Kielty</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Bacteriophages targeting <italic toggle="yes">Acinetobacter baumannii</italic> capsule induce antimicrobial resensitization</article-title><source>Nat. Microbiol.</source><year>2021</year><volume>6</volume><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-00830-7</pub-id><pub-id pub-id-type="pmid">33432151</pub-id></element-citation></ref><ref id="B107-microorganisms-10-01052"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Loh</surname><given-names>B.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Hua</surname><given-names>X.</given-names></name>
<name><surname>Leptihn</surname><given-names>S.</given-names></name>
</person-group><article-title>Colistin-phage combinations decrease antibiotic resistance in <italic toggle="yes">Acinetobacter baumannii</italic> via changes in envelope architecture</article-title><source>Emerg. Microbes Infect.</source><year>2021</year><volume>10</volume><fpage>2205</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.1080/22221751.2021.2002671</pub-id><?supplied-pmid 34736365?><pub-id pub-id-type="pmid">34736365</pub-id></element-citation></ref><ref id="B108-microorganisms-10-01052"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Segall</surname><given-names>A.M.</given-names></name>
<name><surname>Roach</surname><given-names>D.R.</given-names></name>
<name><surname>Strathdee</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy</article-title><source>Curr. Opin. Microbiol.</source><year>2019</year><volume>51</volume><fpage>46</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2019.03.005</pub-id><?supplied-pmid 31226502?><pub-id pub-id-type="pmid">31226502</pub-id></element-citation></ref><ref id="B109-microorganisms-10-01052"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grygorcewicz</surname><given-names>B.</given-names></name>
<name><surname>Roszak</surname><given-names>M.</given-names></name>
<name><surname>Golec</surname><given-names>P.</given-names></name>
<name><surname>&#x0015a;leboda-Taront</surname><given-names>D.</given-names></name>
<name><surname>&#x00141;ubowska</surname><given-names>N.</given-names></name>
<name><surname>G&#x000f3;rska</surname><given-names>M.</given-names></name>
<name><surname>Jursa-Kulesza</surname><given-names>J.</given-names></name>
<name><surname>Rakoczy</surname><given-names>R.</given-names></name>
<name><surname>Wojciuk</surname><given-names>B.</given-names></name>
<name><surname>Do&#x00142;&#x00119;gowska</surname><given-names>B.</given-names></name>
</person-group><article-title>Antibiotics act with vB_AbaP_AGC01 phage against <italic toggle="yes">Acinetobacter baumannii</italic> in human heat-inactivated plasma blood and <italic toggle="yes">Galleria mellonella</italic> models</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>4390</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21124390</pub-id><?supplied-pmid 32575645?><pub-id pub-id-type="pmid">32575645</pub-id></element-citation></ref><ref id="B110-microorganisms-10-01052"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grygorcewicz</surname><given-names>B.</given-names></name>
<name><surname>Wojciuk</surname><given-names>B.</given-names></name>
<name><surname>Roszak</surname><given-names>M.</given-names></name>
<name><surname>&#x00141;ubowska</surname><given-names>N.</given-names></name>
<name><surname>B&#x00142;a&#x0017c;ejczak</surname><given-names>P.</given-names></name>
<name><surname>Jursa-Kulesza</surname><given-names>J.</given-names></name>
<name><surname>Rakoczy</surname><given-names>R.</given-names></name>
<name><surname>Masiuk</surname><given-names>H.</given-names></name>
<name><surname>Do&#x00142;&#x00119;gowska</surname><given-names>B.</given-names></name>
</person-group><article-title>Environmental phage-based cocktail and antibiotic combination effects on <italic toggle="yes">Acinetobacter baumannii</italic> biofilm in a human urine model</article-title><source>Microb. Drug Resist.</source><year>2021</year><volume>27</volume><fpage>25</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1089/mdr.2020.0083</pub-id><pub-id pub-id-type="pmid">32543337</pub-id></element-citation></ref><ref id="B111-microorganisms-10-01052"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blasco</surname><given-names>L.</given-names></name>
<name><surname>Ambroa</surname><given-names>A.</given-names></name>
<name><surname>Trastoy</surname><given-names>R.</given-names></name>
<name><surname>Bleriot</surname><given-names>I.</given-names></name>
<name><surname>Moscoso</surname><given-names>M.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Garc&#x000ed;a</surname><given-names>L.</given-names></name>
<name><surname>Perez-Nadales</surname><given-names>E.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Cuenca</surname><given-names>F.</given-names></name>
<name><surname>Torre-Cisneros</surname><given-names>J.</given-names></name>
<name><surname>Oteo-Iglesias</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>7163</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-64145-7</pub-id><pub-id pub-id-type="pmid">32346029</pub-id></element-citation></ref><ref id="B112-microorganisms-10-01052"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>D.W.</given-names></name>
<name><surname>Jin</surname><given-names>J.S.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
</person-group><article-title>Antimicrobial activity of LysSS, a novel phage endolysin, against <italic toggle="yes">Acinetobacter baumannii</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>J. Glob. Antimicrob. Resist.</source><year>2020</year><volume>22</volume><fpage>32</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2020.01.005</pub-id><pub-id pub-id-type="pmid">32006750</pub-id></element-citation></ref><ref id="B113-microorganisms-10-01052"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jun</surname><given-names>S.Y.</given-names></name>
<name><surname>Jung</surname><given-names>G.M.</given-names></name>
<name><surname>Yoon</surname><given-names>S.J.</given-names></name>
<name><surname>Oh</surname><given-names>M.D.</given-names></name>
<name><surname>Choi</surname><given-names>Y.J.</given-names></name>
<name><surname>Lee</surname><given-names>W.J.</given-names></name>
<name><surname>Kong</surname><given-names>J.C.</given-names></name>
<name><surname>Seol</surname><given-names>J.G.</given-names></name>
<name><surname>Kang</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1</article-title><source>Int. J. Antimicrob. Agents</source><year>2013</year><volume>41</volume><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2012.10.011</pub-id><pub-id pub-id-type="pmid">23276502</pub-id></element-citation></ref><ref id="B114-microorganisms-10-01052"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heselpoth</surname><given-names>R.D.</given-names></name>
<name><surname>Yin</surname><given-names>Y.</given-names></name>
<name><surname>Moult</surname><given-names>J.</given-names></name>
<name><surname>Nelson</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Increasing the stability of the bacteriophage endolysin PlyC using rationale-based FoldX computational modeling</article-title><source>Protein Eng. Des. Sel.</source><year>2015</year><volume>28</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/protein/gzv004</pub-id><pub-id pub-id-type="pmid">25740429</pub-id></element-citation></ref><ref id="B115-microorganisms-10-01052"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garc&#x000ed;a</surname><given-names>R.</given-names></name>
<name><surname>Latz</surname><given-names>S.</given-names></name>
<name><surname>Romero</surname><given-names>J.</given-names></name>
<name><surname>Higuera</surname><given-names>G.</given-names></name>
<name><surname>Garc&#x000ed;a</surname><given-names>K.</given-names></name>
<name><surname>Bast&#x000ed;as</surname><given-names>R.</given-names></name>
</person-group><article-title>Bacteriophage production models: An overview</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><elocation-id>1187</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.01187</pub-id><pub-id pub-id-type="pmid">31214139</pub-id></element-citation></ref><ref id="B116-microorganisms-10-01052"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sochocka</surname><given-names>M.</given-names></name>
<name><surname>Tomczyk</surname><given-names>T.</given-names></name>
<name><surname>Sobczy&#x00144;ski</surname><given-names>M.</given-names></name>
<name><surname>Szermer-Olearnik</surname><given-names>B.</given-names></name>
<name><surname>Boraty&#x00144;ski</surname><given-names>J.</given-names></name>
</person-group><article-title>The kinetics of <italic toggle="yes">Escherichia coli</italic> B growth and bacteriophage T4 multiplication in SM-1 novel minimal culture medium</article-title><source>J. Gen. Appl. Microbiol.</source><year>2015</year><volume>61</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.2323/jgam.61.75</pub-id><pub-id pub-id-type="pmid">26227910</pub-id></element-citation></ref><ref id="B117-microorganisms-10-01052"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nabergoj</surname><given-names>D.</given-names></name>
<name><surname>Kuzmi&#x00107;</surname><given-names>N.</given-names></name>
<name><surname>Drakslar</surname><given-names>B.</given-names></name>
<name><surname>Podgornik</surname><given-names>A.</given-names></name>
</person-group><article-title>Effect of dilution rate on productivity of continuous bacteriophage production in cellstat</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>3649</fpage><lpage>3661</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-8893-9</pub-id><?supplied-pmid 29516149?><pub-id pub-id-type="pmid">29516149</pub-id></element-citation></ref><ref id="B118-microorganisms-10-01052"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Warner</surname><given-names>C.M.</given-names></name>
<name><surname>Barker</surname><given-names>N.</given-names></name>
<name><surname>Lee</surname><given-names>S.-W.</given-names></name>
<name><surname>Perkins</surname><given-names>E.J.</given-names></name>
</person-group><article-title>M13 bacteriophage production for large-scale applications</article-title><source>Bioprocess Biosyst. Eng.</source><year>2014</year><volume>10</volume><fpage>2067</fpage><lpage>2072</lpage><pub-id pub-id-type="doi">10.1007/s00449-014-1184-7</pub-id><?supplied-pmid 24728964?><pub-id pub-id-type="pmid">24728964</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="microorganisms-10-01052-f001"><label>Figure 1</label><caption><p>Schematic representation of the virulence factors associated with <italic toggle="yes">A. baumannii</italic> virulome. Cellular Envelope Factors (desiccation resistance, in vivo survival, evasion of host immune response): LPS&#x02014;Lipopolysaccharide; CPS&#x02014;Capsular polysaccharide; Outer Membrane Proteins (OMPs) (adherence, invasion, and cytotoxicity): OmpA&#x02014;Outer membrane protein A; CarO&#x02014;Carbapenem susceptible porin; SS &#x02013; Secretions Systems (inter- and intraspecies competition, adherence, nutrient acquisition, in vivo survival): Sec&#x02014;Secretory pathway; Tat&#x02014;Twin-arginine system; T2SS&#x02014;Type II secretion system; T5SS&#x02014;Type V secretion system; T5bSS&#x02014;Type Vb secretion system; T5cSS&#x02014;Type Vc secretion system; CDI&#x02014;Contact-dependant inhibition; Ata&#x02014;<italic toggle="yes">Acinetobacter</italic> trimeric autotransporter; T6SS&#x02014;Type VI secretion system; Phospholipases (invasion, in vivo survival): PLD&#x02014;Phospholipase D; PLC&#x02014;Phospholipase C; Twitching and Swarming Motility (in vivo virulence): T4P or TFP&#x02014;Type IV pili; Biofilm Formation (environmental survival, adherence, and intracellular communication): Cus pili&#x02014;Chaperone-usher pili; PNAG&#x02014;Poly-&#x003b2;-(1-6)-N-acetylglucosamine; BAP or Bap&#x02014;Biofilm-associated protein; eDNA&#x02014;Extracellular DNA (structures not drawn to scale; adapted from Harding et al. [<xref rid="B16-microorganisms-10-01052" ref-type="bibr">16</xref>]).Two T5SS have been identified amongst <italic toggle="yes">Acinetobacter</italic> spp., namely, Type Vb (T5bSS) and Type Vc (T5cSS). The T5bSS are classified as two-partner secretion (TPS) systems and have been found to be associated with increased adherence to human epithelial alveolar (A549) cells, and in vivo virulence in nematodes (<italic toggle="yes">Caenorhabditis elegans</italic>) and murine (BALB/c mice) models [<xref rid="B43-microorganisms-10-01052" ref-type="bibr">43</xref>]. Another T5bSS, the contact-dependent growth inhibition (CDI) system or CdiA/CdiB system, facilitates bacterial competition through the secretion of the CdiA toxin into the cytoplasm of neighbouring bacteria [<xref rid="B44-microorganisms-10-01052" ref-type="bibr">44</xref>] (<xref rid="microorganisms-10-01052-f001" ref-type="fig">Figure 1</xref>). Apart from T5bSS, the T5cSS, the <italic toggle="yes">Acinetobacter</italic> trimeric autotransporter (Ata) type Vc secretion system, has been described as multifactorial, facilitating biofilm formation, extracellular matrix/basal membrane protein (collagen IV cell) adhesion, as well as pathogenesis in murine (C57BL/6 mice) models (<xref rid="microorganisms-10-01052-f001" ref-type="fig">Figure 1</xref>). The Type VI secretion system (T6SS) is primarily associated with bacterial competition (secretions of peptidoglycan hydrolyses and nucleases) and has also been observed to contribute to in vivo virulence in a larva [<italic toggle="yes">Galleria mellonella</italic> (<italic toggle="yes">G. mellonella</italic>)] model [<xref rid="B16-microorganisms-10-01052" ref-type="bibr">16</xref>,<xref rid="B45-microorganisms-10-01052" ref-type="bibr">45</xref>]. This secretion system further facilitates virulence through the release of phospholipases of which phospholipase C (PLC) and phospholipase D (PLD) have been detected and described for <italic toggle="yes">A. baumannii</italic> strains. Three PLDs (PLD1, PLD2, and PLD3) have then been found to mediate human serum resistance (higher propensity to cause bacteraemia), invasion of human bronchial epithelial cells (BEAS-2B), and pathogenicity in murine (C57BL/6 mice) models and larva (<italic toggle="yes">G. mellonella</italic>) models [<xref rid="B46-microorganisms-10-01052" ref-type="bibr">46</xref>] (<xref rid="microorganisms-10-01052-f001" ref-type="fig">Figure 1</xref>). For example, the authors observed that <italic toggle="yes">pld</italic> triple mutants (&#x00394;<italic toggle="yes">pld1-3</italic> triple mutant) exhibited a reduced (74.2 &#x000b1; 3.6%) in vivo virulence in comparison to wild-type <italic toggle="yes">A. baumannii</italic> (89.8 &#x000b1; 2.6%), highlighting the role of phospholipase in the pathogenesis of this opportunistic bacterium. Furthermore, PLC has been observed to contribute to human epithelial cell (FaDu) cytotoxicity, however, only under nutrient-rich conditions and during exposure to chemical stressors such as ethanol [<xref rid="B47-microorganisms-10-01052" ref-type="bibr">47</xref>].</p></caption><graphic xlink:href="microorganisms-10-01052-g001" position="float"/></fig><fig position="float" id="microorganisms-10-01052-f002"><label>Figure 2</label><caption><p>(<bold>A</bold>) Proposed biosurfactant (surfactin) modes of action on Gram-negative bacterium as indicated by (A1) insertion of biosurfactant fatty acid moiety, (A2) membrane disintegration, (A3) pore formation. (<bold>B</bold>) Surfactin resistance mechanisms described amongst <italic toggle="yes">B. subtilis</italic> strains; (B1) RND-like family efflux pump or other PMF dependant transporter and; (B2) Cardiolipin incorporation (adapted from Li et al. [<xref rid="B12-microorganisms-10-01052" ref-type="bibr">12</xref>]; Balleza et al. [<xref rid="B70-microorganisms-10-01052" ref-type="bibr">70</xref>]; Pinkas et al. [<xref rid="B13-microorganisms-10-01052" ref-type="bibr">13</xref>]). LPS&#x02014;Lipopolysaccharide; LOS&#x02014;Lipooligosaccharide; RND&#x02014;Resistance-nodulation-division.</p></caption><graphic xlink:href="microorganisms-10-01052-g002" position="float"/></fig><fig position="float" id="microorganisms-10-01052-f003"><label>Figure 3</label><caption><p>Schematics representation of the proposed life cycle of <italic toggle="yes">B. bacteriovorus</italic> (predator) preying on Gram-negative bacterium (prey): (<bold>A</bold>) Attack phase; (<bold>B</bold>) Periplasmic growth phase; (<bold>C</bold>) Host-independent (HI) phase; (<bold>D</bold>) Proposed predation resistance mechanisms including population-based resistance (plastic phenotypic resistance) and cell wall-based resistance mechanisms (production of procrystalline protein or S-layer) (adapted from Shemesh and Jurkevitch [<xref rid="B84-microorganisms-10-01052" ref-type="bibr">84</xref>]; Marine et al. [<xref rid="B82-microorganisms-10-01052" ref-type="bibr">82</xref>]). The in vivo antimicrobial activity of <italic toggle="yes">B. bacteriovorus</italic> has also been demonstrated, with Shatzkes et al. [<xref rid="B87-microorganisms-10-01052" ref-type="bibr">87</xref>] applying the <italic toggle="yes">B. bacteriovorus</italic> 109J strain to murine (SD rats) models infected with a lethal dose (3.3 &#x000d7; 10<sup>7</sup> CFU/rat) of <italic toggle="yes">K. pneumoniae</italic> ATCC 43816. The predator strain significantly reduced (99.9%) <italic toggle="yes">K. pneumoniae</italic> ATCC 43816 cell counts in vivo, with no adverse effects observed following treatment. In addition, Findlay et al. [<xref rid="B88-microorganisms-10-01052" ref-type="bibr">88</xref>] demonstrated the efficiency of <italic toggle="yes">B. bacteriovorus</italic> HD100 pre-treatment in a murine model (SKH-1 mice) against a lethal infection (~1000 CFU/100 &#x003bc;L) of <italic toggle="yes">Yersinia pestis</italic> (<italic toggle="yes">Y. pestis</italic>) CO92. The <italic toggle="yes">Y. pestis</italic> CO92 cell counts were significantly reduced (&#x0003c;10 CFU) following administration to the <italic toggle="yes">B. bacteriovorus</italic> HD100 pre-treated murine (SKH-1 mice) models. Additionally, to date, deleterious effects, following the application of <italic toggle="yes">B. bacteriovorus</italic> by ingestion and/or injection, have not been reported, which further validates the application of the predatory bacteria as a potential biological control strategy for the treatment of MDR, XDR, or PDR <italic toggle="yes">A. baumannii</italic> strains [<xref rid="B89-microorganisms-10-01052" ref-type="bibr">89</xref>].</p></caption><graphic xlink:href="microorganisms-10-01052-g003" position="float"/></fig><fig position="float" id="microorganisms-10-01052-f004"><label>Figure 4</label><caption><p>Schematics representation of the (<bold>A</bold>) lytic and (<bold>B</bold>) lysogenic bacteriophage life cycles and (<bold>C</bold>) bacteriophage resistance mechanisms, including receptor adaptations (adsorption inhibitions and injection blocking), host defence systems [clustered regularly interspaced short palindromic repeats (CRISPR/Cas)] and phage-derived defence systems (restriction and modification) (adapted from Hyman and Abedo [<xref rid="B97-microorganisms-10-01052" ref-type="bibr">97</xref>]; Egido et al. [<xref rid="B98-microorganisms-10-01052" ref-type="bibr">98</xref>]). The pharmaceutical and medical application of bacteriophages has also garnered renewed interest globally, due to the rise in the frequency of antibiotic-resistant bacterial infections and the limited availability of new antimicrobial compounds [<xref rid="B99-microorganisms-10-01052" ref-type="bibr">99</xref>]. For example, Merabishvili et al. [<xref rid="B42-microorganisms-10-01052" ref-type="bibr">42</xref>] isolated two bacteriophages, namely, vB_AbaM_Acibel004 (<italic toggle="yes">Myoviridae</italic>) and vB_AbaP_Acibel007 (<italic toggle="yes">Podoviridae</italic>), with Acibel004 exhibiting antibacterial activity towards 75% (<italic toggle="yes">n</italic> = 21/28) of the <italic toggle="yes">A. baumannii</italic> test isolates, while Acibel007 exhibited antibacterial activity towards 60.7% (<italic toggle="yes">n</italic> = 17/28) of the isolates analysed. Correspondingly, Asif et al. [<xref rid="B100-microorganisms-10-01052" ref-type="bibr">100</xref>] isolated a <italic toggle="yes">Myoviridae</italic> bacteriophage (TAC1), which shared high genetic similarity to the <italic toggle="yes">Myoviridae</italic> bacteriophage Acibel004 [<xref rid="B4-microorganisms-10-01052" ref-type="bibr">4</xref>] and exhibited antibacterial activity against 66% (<italic toggle="yes">n</italic> = 21/32) of the MDR <italic toggle="yes">A. baumannii</italic> strains tested.</p></caption><graphic xlink:href="microorganisms-10-01052-g004" position="float"/></fig><table-wrap position="float" id="microorganisms-10-01052-t001"><object-id pub-id-type="pii">microorganisms-10-01052-t001_Table 1</object-id><label>Table 1</label><caption><p>Antibiotic resistance mechanisms associated with <italic toggle="yes">A. baumannii</italic> (adapted from Lee et al. [<xref rid="B17-microorganisms-10-01052" ref-type="bibr">17</xref>]).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antibiotic (s)</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Resistance Mechanism (s)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Location (s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Example (s)</th></tr></thead><tbody><tr><td rowspan="21" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x003b2;-lactams</td><td rowspan="21" colspan="2" align="center" valign="middle" style="border-bottom:solid thin">Enzymatic</td><td rowspan="10" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ambler Class A</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C and P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CTX-M-1, CTX-M-2, CTX-M-5, CTX-M-8, CTX-M-9, CTX-M-15, and CTX-M-43</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C and P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CARB-4 and CARB-10</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GES-1, GES-5, GES-11, and GES-14</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KPC-2, KPC-3, KPC-5, and KPC-10</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C and P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PER-1, PER-2, PER-3, PER-7, and PER-8</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCO-1</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPM-1</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SHV-5, SHV-12, and SHV-14</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TEM-1, TEM-92, and TEM-116</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C, P and I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEB-1, VEB-3 and VEB-7</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ambler Class B or metallo-&#x003b2;-lactamase</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IMP-1, IMP-2, IMP-4, IMP-5, IMP-6, IMP-8, IMP-11, IMP-14; IMP-19, and IMP-55</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C and P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NDM-1, NDM-2, and NDM-3</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIM-1</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VIM-1, VIM-2, VIM-3, VIM-4, and VIM-11</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ambler Class C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AmpC</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ADC-1&#x02013;ADC-81</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ambler Class D</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C and P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OXA-23 subtype: OXA-23, OXA-27, OXA-49, OXA-73, OXA-102, OXA-103, OXA-105, OXA-133, OXA-134, OXA-146, OXA-165, OXA-171, OXA-225, and OXA-239</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C and P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OXA-24/40 subtype: OXA-25, OXA-26, OXA-27, OXA-40, OXA-72, OXA-143, OXA-160, OXA-182, and OXA-207</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C and P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OXA-51 subtype: OXA-51, OXA-64&#x02013;OXA-71, OXA-75&#x02013;OXA-80, OXA-82&#x02013;OXA-84, OXA-86&#x02013;OXA-95, OXA-98&#x02013;OXA-100, OXA-104, OXA-106&#x02013;OXA-113, OXA-115&#x02013;OXA-117, OXA-120&#x02013;OXA-128, OXA-130&#x02013;OXA-132, OXA-138, OXA -144, OXA-148&#x02013;OXA-150, OXA-172&#x02013;OXA-180, OXA-194&#x02013;OXA-197, OXA-200&#x02013;OXA-203, OXA-206, OXA-208, OXA-216, OXA-217, OXA-219, OXA-223, OXA-241, OXA-242, OXA-248&#x02013;OXA-250, and OXA-254</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C and P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OXA-58 subtype: OXA-58, OXA-96, OXA-97, and OXA-164</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">C and P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OXA-143 subtype: OXA-143, OXA-182, OXA-231, OXA-253, and OXA-255</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Antibiotic (s)</bold>
</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Resistance Mechanism (s)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Location (s)</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Example (s)</bold>
</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#x003b2;-lactams</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Permeability defects </td><td rowspan="2" colspan="2" align="center" valign="middle" style="border-bottom:solid thin">OMP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">CarO</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">OmpA, Omp33, OmpB, Omp25, OmpC, OmpD, and OmpW</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Efflux pumps </td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">RND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">AdeABC</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target mutation</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">PBP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">PBP6b (dacD)</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Aminoglycosides </td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Enzymatic </td><td rowspan="3" colspan="2" align="center" valign="middle" style="border-bottom:solid thin">AME</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">C, P, and I</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">AAC: <italic toggle="yes">aac(6&#x02032;)-Ib</italic>&#x02019;<italic toggle="yes">, aac(3)-IIa, aac(3&#x02032;)-Ia,</italic> and <italic toggle="yes">aac(3&#x02032;)IIa</italic>
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">ANT: <italic toggle="yes">ant(3&#x02032;</italic>&#x02019;<italic toggle="yes">)-IIa, ant(2&#x02032;</italic>&#x02019;<italic toggle="yes">)-Ia, ant(2&#x02032;)-Ia,</italic> and <italic toggle="yes">ant(3&#x02032;</italic>&#x02019;<italic toggle="yes">)-IIa;</italic>
</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">APH: <italic toggle="yes">aph(3&#x02032;)-VI, aph(3&#x02032;)-Via, aph(3&#x02032;</italic>&#x02019;<italic toggle="yes">)-Ib, aph(6)-Id,</italic> and <italic toggle="yes">aph(3&#x02032;)-VIa</italic></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Target mutation</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">RMTases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><italic toggle="yes">armA, rmtA, rmtB, rmtC,</italic> and <italic toggle="yes">rmtD</italic></td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Efflux pumps </td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">RND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">AdeABC</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">MATE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">AdeM</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Quinolones </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target mutation</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">DNA gyrase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">GyrA</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">DNA topoisomerase </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">ParC</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Efflux pumps </td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">RND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">AdeABC and AdeIJK </td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">MATE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">AbeM</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tetracyclines and Glycylines </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Efflux pumps </td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">RND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C and P</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">AdeABC, AdeIJK, and AcrAB-TolC</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">MFS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">TetA and TetB</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ribosomal protection</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Ribosomal dissociation </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Tet(O) and Tet(M) </td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Polymyxins </td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Target mutation </td><td rowspan="2" colspan="2" align="center" valign="middle" style="border-bottom:solid thin">Lipid A modification</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">PmrA, PmrB, and PmrC</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1"><italic toggle="yes">mcr-1</italic> and <italic toggle="yes">mcr-4.3</italic></td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Lipid A loss</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">LpxA, LpxC, and LpxD</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Membrane stability </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">LpsB, LptD, and VacJ</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Biotin synthesis </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">LpsB</td></tr></tbody></table><table-wrap-foot><fn><p>AAC&#x02014;Acetyltransferases; ADC&#x02014;<italic toggle="yes">Acinetobacter</italic>-derived cephalosporinases; AME&#x02014;Aminoglycoside-modifying enzymes; ANT&#x02014;Nucleotidyltransferases; APH&#x02014;phosphotransferases; C&#x02014;Chromosome (Chromosomal); CARB&#x02014;Carbenicillin-hydrolysing &#x003b2;-lactamases; CTX-M&#x02014;Cefotaximase-Munich; GES&#x02014;Guiana extended spectrum; I&#x02014;Integron; IMP&#x02014;Imipenem metallo-&#x003b2;-lactamase; KPC&#x02014;<italic toggle="yes">Klebsiella pneumoniae</italic> carbapenemase; MATE&#x02014;Multiple antibiotic and toxin extrusion; MFS&#x02014;major facilitator super family; NDM&#x02014;New Delhi metallo-&#x003b2;-lactamase; OMP&#x02014;Outer membrane protein; OXA&#x02014;Oxacillinase; P&#x02014;Plasmid; PBP&#x02014;Penicillin-binding protein; PER&#x02014;<italic toggle="yes">Pseudomonas</italic> extended resistance; RMTases&#x02014;16S RNA methylase; RND&#x02014;Resistance-nodulation-division; SCO&#x02014;Novel class A &#x003b2;-lactamase; SHV&#x02014;Sulfhydryl variant; SIM&#x02014;Seoul imipenem metallo-&#x003b2;-lactamase; SPM&#x02014;S&#x000e3;o Paulo metallo-&#x003b2;-lactamase; TEM&#x02014;Temoniera; VEB&#x02014;Vietnam extended spectrum &#x003b2;-lactamase; VIM&#x02014;Verona integrin-encoded metallo-&#x003b2;-lactamase.</p></fn></table-wrap-foot></table-wrap></floats-group></article>